[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 616
1. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Vougioukas VI, Gläsker S, Hubbe U, Berlis A, Omran H, Neumann HP, Van Velthoven V: Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients. Childs Nerv Syst; 2006 Sep;22(9):1149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemangioblastomas are histologically benign lesions that occur sporadically or as a manifestation of von Hippel-Lindau disease (VHL).
  • The treatment strategy of these neoplasms is complicated by their unpredictable growth patterns and the often irreversible neurological deficits they may cause.
  • Ten patients were affected by von Hippel-Lindau and three were with sporadic tumors.
  • Two patients with brainstem tumors exhibited transient hemiparesis and caudal nerve palsy, respectively.
  • Preoperatively symptomatic patients with spinal tumors did not deteriorate nor improve after surgery.
  • During the observed follow-up periods, no tumor recurrences were observed.
  • Molecular screening of every pediatric patient and family is mandatory to enable the detection of extraneurological tumors and the development of an efficient therapeutic strategy.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Cerebellar Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adolescent. Brain Stem / pathology. Brain Stem / surgery. Cerebellum / pathology. Cerebellum / surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neurologic Examination. Postoperative Complications / diagnosis. Spinal Cord / pathology. Spinal Cord / surgery

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):82-94 [12546356.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):898-901 [1431953.001]
  • [Cites] J Med Genet. 1990 May;27(5):311-4 [2352258.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):24-30 [2909683.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17 (3):525-31 [8881249.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62 [10567493.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):695-8 [2586723.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):106-16 [12546358.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):257-60 [11835384.001]
  • [Cites] Neurosurgery. 1988 Mar;22(3):518-22 [3129668.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):321-7; discussion 327-8 [11504107.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):95-105 [12546357.001]
  • [Cites] Neurosurgery. 2003 Dec;53(6):1306-13; discussion 1313-4 [14633297.001]
  • (PMID = 16369852.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Josan V, Smith P, Kornberg A, Rickert C, Maixner W: Development of a pilocytic astrocytoma in a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg; 2007 Jun;106(6 Suppl):509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a pilocytic astrocytoma in a dysembryoplastic neuroepithelial tumor. Case report.
  • Dysembryoplastic neuroepithelial tumors (DNETs) are benign supratentorial tumors based in the cerebral cortex.
  • When tumors thought to be DNETs are not resected due to their proximity to eloquent cortex, lack of change in the clinical and neuroimaging features over time supports the diagnosis of DNET.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cerebral Cortex. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis. Neuroectodermal Tumors, Primitive / diagnosis


Advertisement
4. Jinhu Y, Jianping D, Jun M, Hui S, Yepeng F: Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature. J Neurooncol; 2007 May;83(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature.
  • Cerebrospinal metastases of benign choroid plexus papillomas (CPPs) are extremely rare.
  • Plain CT scan of the cranium revealed a partly calcified tumor filling the fourth ventricle and its right recess.
  • Cranial MRI showed an inhomogeneously contrast-enhancing tumor and leptomeningeal enhancement encasing the brain stem.
  • Complete resection of the tumor was carried out, and seedings to the floor of the fourth ventricle and cervico-medullary junction were found during the operation.
  • While intraoperative frozen section suggested pathology of papillary ependymoma or CPP, to our surprise, final histological examination revealed a benign choroid plexus papilloma.
  • Two months after the first operation, on follow-up MRI of the cranium, the leptomeningeal enhancement encasing the brain stem had resolved spontaneously.
  • This special case helps increase our understanding of benign CPPs and expands our differential diagnostic consideration of lesions with similar manifestations.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Cerebral Ventricle Neoplasms / secondary. Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / secondary. Fourth Ventricle. Papilloma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Seeding. Neurosurgical Procedures / adverse effects. Subarachnoid Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1970 Nov;110(3):608-17 [5489698.001]
  • [Cites] Surg Neurol. 1999 Jun;51(6):621-9 [10369230.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Sep;100(3):165-86 [9822838.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jan;33(1):32-5 [7680781.001]
  • [Cites] Neurochirurgie. 1986;32(3):258-61 [3762840.001]
  • [Cites] Neurosurg Focus. 2006 Jan 15;20(1):E10 [16459990.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jul;101(7):366-8 [577391.001]
  • [Cites] Neuroradiology. 2000 Sep;42(9):657-61 [11071438.001]
  • [Cites] Pediatr Neurosci. 1985-1986;12(4-5):196-201 [3843618.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Br J Radiol. 1992 Sep;65(777):754-7 [1393408.001]
  • [Cites] Neurology. 2005 Sep 27;65(6):842 [16186520.001]
  • [Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):85-90 [8744814.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):564-5 [2058519.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):469-72 [3111207.001]
  • [Cites] Surg Neurol. 1982 Nov;18(5):367-71 [6983728.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):723-8 [12181706.001]
  • [Cites] Neurology. 1995 Oct;45(10):1801-7 [7477972.001]
  • [Cites] Neurosurg Rev. 1981;4(3):129-37 [7301142.001]
  • [Cites] Aust N Z J Med. 1997 Oct;27(5):597-8 [9404596.001]
  • [Cites] Folia Neuropathol. 2001;39(3):209-13 [11770132.001]
  • [Cites] Surg Neurol. 1987 May;27(5):466-8 [3563861.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):633-8 [8010262.001]
  • (PMID = 17387433.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


5. Hernández Faraco A, Céspedes G, Trejo E: [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. Neurologia; 2009 May;24(4):235-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Expresión inmunohistoquímica del receptor de progesterona en relación con el grado histológico y riesgo de recidivas en meningiomas intracraneanos.
  • INTRODUCTION: Meningiomas are frequent primary neoplasms of the central nervous system, usually benign and susceptible to healing through surgery.
  • The histological grade of the WHO and the extension of the initial surgical resection are determining prognostic factors in these tumors.
  • Nevertheless, a recurrence rate close to 20 % in benign meningiomas completely diseccated arises the need of considering new prognostic factors.
  • RESULTS: Though the immunohistochemical labelling index (LI) of the PR decreased with the progression of the histological grade (means of 27.37 % for grade I, 17.89% for grade II, and 13.50% for grade III), such correlation was not statistically significant and the cut off estimated in 20% was not satisfactory to discriminate among benign meningiomas (grade I) and non benign (grades II-III) due to its poor sensitivity (56.10%) and positive predictive value (56.10 %).
  • The comparison of the LI of the PR among non recurrent meningiomas (36.35 %) and recurrent (22.10%) was neither statistically significant, but permitted to establish a useful cut off of 40% (LI >40% in 13/23 non recurrent tumors and <40% in 19/23 recurrent tumors) with a sensitivity of 82.61% and a positive predictive value of 65.52%.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Receptors, Progesterone / biosynthesis
  • [MeSH-minor] Adult. Biomarkers, Tumor. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603293.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone
  •  go-up   go-down


6. Kantar M, Sezak M, Turhan T, Kitis O, Mutluer S, Demirag BK, Aksoylar S, Akalin T, Ersahin Y, Cetingul N: Melanotic progonoma of the skull in infancy. Childs Nerv Syst; 2008 Nov;24(11):1371-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Melanotic progonoma or melanotic neuroectodermal tumor is a rare tumor in infancy.
  • This lesion has to be considered in the differential diagnosis of benign or malignant lesions of calvarium.
  • The tumor was removed by surgery.
  • A tumor, brownish-black in color, was diagnosed as melanotic progonoma.
  • Benign or malignant lesions may occur as lumps on calvarium.
  • Benign or malignant lesions can be differentiated by craniography, CT, or MRI scans, but exact diagnosis of melanotic progonoma is made by histopathology and immunostaining, as was in the presented case.
  • The tumors usually do not recur in long-term period.
  • [MeSH-major] Neuroectodermal Tumor, Melanotic / diagnostic imaging. Neuroectodermal Tumor, Melanotic / pathology. Skull Neoplasms / diagnostic imaging. Skull Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Craniofac Surg. 2007 Mar;18(2):450-4 [17414302.001]
  • [Cites] Childs Nerv Syst. 1995 Mar;11(3):186-8 [7773982.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):34-43 [14986932.001]
  • [Cites] Indian J Pathol Microbiol. 2005 Jul;48(3):363-4 [16761753.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):661-6 [6305482.001]
  • [Cites] Pediatr Neurosurg. 1992;18(1):6-15 [1329922.001]
  • [Cites] Histopathology. 2000 Mar;36(3):283-5 [10809600.001]
  • [Cites] Ann Diagn Pathol. 2004 Aug;8(4):207-12 [15290671.001]
  • [Cites] J AAPOS. 2007 Oct;11(5):504-5 [17532239.001]
  • [Cites] Neuroradiology. 1999 Mar;41(3):202-4 [10206168.001]
  • [Cites] Surg Neurol. 2005 Mar;63(3):275-80 [15734527.001]
  • [Cites] Med Pediatr Oncol. 2003 Mar;40(3):198-9 [12518354.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):175-8 [10414583.001]
  • [Cites] Brain Pathol. 2006 Oct;16(4):333-4 [17107603.001]
  • [Cites] Childs Nerv Syst. 1998 Aug;14(8):389-93 [9753407.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Oct-Nov;23(7):579-86 [16928653.001]
  • [Cites] Radiol Med. 1991 Mar;81(3):213-24 [2014322.001]
  • [Cites] Ann Pathol. 2002 Feb;22(1):52-5 [11938002.001]
  • (PMID = 18592253.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • Therefore, our first pathological diagnosis was oligoastrocytoma and DNT.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Langevin CJ, Hanasono MM, Riina HA, Stieg PE, Spinelli HM: Lateral transzygomatic approach to sphenoid wing meningiomas. Neurosurgery; 2010 Dec;67(2 Suppl Operative):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sphenoid wing meningiomas are slow-growing, well-circumscribed, and histologically benign lesions.
  • To achieve maximal exposure and minimal brain retraction, a lateral transzygomatic approach with osteotomies of the entire zygoma, which remains pedicled on the masseter muscle, was used.
  • CONCLUSION: The lateral transzygomatic approach to the sphenoid wing can be performed safely with minimal morbidity and facilitates complete resection of the tumor.
  • This approach belongs in the armamentarium of surgeons who are involved in the resection of skull base neoplasms.
  • [MeSH-major] Craniotomy / methods. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / methods. Skull / surgery. Zygoma / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099561.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lui PC, Fan YS, Wong SS, Chan AN, Wong G, Chau TK, Tse GM, Cheng Y, Poon WS, Ng HK: Inflammatory pseudotumors of the central nervous system. Hum Pathol; 2009 Nov;40(11):1611-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The brain is a rare site of occurrence.
  • All 4 cases displayed typical histological features of inflammatory pseudotumor with dense lymphoplasmacytic infiltrate admixed with small number of benign-looking spindle cells in a collagenous stroma.
  • Hence, a trial of corticosteroid after histological confirmation may be valid to avoid unnecessary risk-taking neurosurgical procedures or in cases with incomplete tumor removal.
  • [MeSH-major] Brain Diseases / pathology. Granuloma, Plasma Cell / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656549.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


10. Gu TF, Xiao XL, Sun F, Yin JH, Zhao H: Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases. Chin Med Sci J; 2008 Sep;23(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases.
  • OBJECTIVE: To evaluate the values of whole body diffusion weighted imaging (DWI) in screening primary unknown tumor in patients with metastases.
  • METHODS: Totally, 34 patients with metastases of primary unknown tumors were scanned with whole body DWI, and conventional magnetic resonance (MR) imaging was performed if suspected lesions were detected.
  • All the metastases including 27 cases of osseous metastases, 2 brain metastases, 2 liver metastases, 1 pulmonary multiple metastasis, 1 neck metastasis and 1 malignant ascites, were diagnosed by computed tomography, single photon emission computed tomography, or MR imaging.
  • For the proven primary tumors diagnosed by biopsy or pathology of surgical specimens, apparent diffusion coefficient (ADC) values of the primary and metastatic lesions were measured respectively.
  • The sensitivity and specificity of this technique for screening primary tumors were evaluated.
  • RESULTS: We found 24 cases with suspected primary lesions, in which 23 lesions were proved to be primary tumors, and 1 was proved to be benign lesion.
  • And no definite primary lesion was found in 10 cases on whole body DWI, but in which 1 case was diagnosed with primary tumor by biopsy later, and the other 9 cases remained unknown within follow-up of over half a year.
  • The sensitivity and specificity of whole body DWI for searching primary tumors was 95.8% and 90.0%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853848.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Degaki TL, Demasi MA, Sogayar MC: Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line. J Steroid Biochem Mol Biol; 2009 Nov;117(4-5):107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line.
  • Upon searching for glucocorticoid-regulated cDNA sequences associated with the transformed to normal phenotypic reversion of C6/ST1 rat glioma cells, we identified Nrp/b (nuclear restrict protein in brain) as a novel rat gene.
  • Among rat tissues, Nrp/b expression is more pronounced in brain tissue.
  • We show that overexpression of the Nrp/b cDNA in C6/ST1 cells suppresses anchorage independence in vitro and tumorigenicity in vivo, altering their malignant nature towards a more benign phenotype.
  • Therefore, Nrp/b may be postulated as a novel tumor suppressor gene, with possible relevance for glioblastoma therapy.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Microfilament Proteins / genetics. Neuropeptides / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Blotting, Western. Cell Line, Tumor. Cloning, Molecular. DNA, Complementary. Gene Expression Regulation. Humans. Immunohistochemistry. Molecular Sequence Data. Rats. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682578.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Microfilament Proteins; 0 / Neuropeptides; 0 / Nuclear Proteins; 0 / ectodermal-neural cortex 1 protein
  •  go-up   go-down


12. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


13. Tsitouridis I, Michaelides M, Bintoudi A, Kyriakou V: Frontoethmoidal Mucoceles: CT and MRI Evaluation. Neuroradiol J; 2007 Oct 31;20(5):586-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a benign slow growing epithelial lined lesion, bulging against adjacent anatomical structures, without infiltrating them.
  • CT scans displayed mucoceles as non enhancing soft tissue density lesions, generally isodense to the brain parenchyma, expanding the sinuses in most cases, eroding adjacent bones and extending intraorbitally or intracranially.
  • No underlying malignant tumor was found in any of the cases as the cause of obstruction.
  • CT and MRI established the correct diagnosis in all patients.
  • CT was more sensitive in determining bone erosions, while MRI had the advantage of multiplanar imaging and was much more sensitive for differentiating mucocele from a tumor on the basis of MR signal intensity characteristics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24299951.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ: Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol; 2009 Oct;36(7):779-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
  • The purpose of this study was to compare the diagnostic value of positron emission tomography (PET) using [(18)F]-fluorodeoxyglucose ((18)F-FDG) and O-(2-[(18)F]fluoroethyl)-l-tyrosine ((18)F-FET) in patients with brain lesions suspicious of cerebral gliomas.
  • METHODS: Fifty-two patients with suspicion of cerebral glioma were included in this study.
  • The cerebral accumulation of (18)F-FDG was calculated by decay corrected subtraction of the (18)F-FET scan from the (18)F-FET/(18)F-FDG scan.
  • RESULTS: Histology revealed 24 low-grade gliomas (LGG) of World Health Organization (WHO) Grade II and 19 high-grade gliomas (HGG) of WHO Grade III or IV, as well as nine others, mainly benign histologies.
  • The gliomas showed increased (18)F-FET uptake (>normal brain) in 86% and increased (18)F-FDG uptake (>white matter) in 35%. (18)F-FET PET provided diagnostically useful delineation of tumor extent while this was impractical with (18)F-FDG due to high tracer uptake in the gray matter.
  • A local maximum in the tumor area for biopsy guidance could be identified with (18)F-FET in 76% and with (18)F-FDG in 28%.
  • In some benign lesions like abscesses, increased uptake was observed for both tracers indicating a limited specificity of both techniques.
  • CONCLUSIONS: (18)F-FET PET is superior to (18)F-FDG for biopsy guidance and treatment planning of cerebral gliomas.
  • The uptake of (18)F-FDG is associated with prognosis, but the predictive value is limited and a histological evaluation of tumor tissue remains necessary.
  • Therefore, amino acids like (18)F-FET are the preferred PET tracers for the clinical management of cerebral gliomas.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720290.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


15. Chittiboina P, Zhang S, Bao J, Vannemreddy P, Guthikonda B: Subependymoma at the foramen of Monro presenting with intermittent hydrocephalus: case report and review of the literature. J La State Med Soc; 2010 Jul-Aug;162(4):214-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymomas are benign neoplasms, accounting for 0.5 % of all central nervous system tumors.
  • These tumors are frequently asymptomatic, often discovered incidentally at autopsy.
  • However, patients may be symptomatic with the symptoms depending on location of the tumor.
  • The patient's tumor was asymptomatic for many years.
  • Even though our patient presented with a histologically benign ventricular tumor, she demonstrated rapidly worsening symptoms that culminated in herniation.
  • Once diagnosed, we recommend early tumor removal and restoration of normal cerebrospinal fluid (CSF) pathways for these intraventricular tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Ventricles. Glioma, Subependymal / diagnosis. Hydrocephalus / etiology

  • Genetic Alliance. consumer health - Hydrocephalus.
  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882814.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sentürk S, Oğuz KK, Cila A: Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. Diagn Interv Radiol; 2009 Mar;15(1):3-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner.
  • PURPOSE: To determine whether there are statistically significant differences in cerebral blood volume (CBV) and cerebral blood flow (CBF) of brain tumors of different histopathologic types including primary and secondary benign and malignant lesions.
  • To determine whether these measurements relate to tumor grade.
  • MATERIALS AND METHODS: Forty-five patients with brain tumors, age 2 to 79 years, underwent dynamic contrast-enhanced susceptibility- weighted echo-planar perfusion magnetic resonance imaging (MRI) using a 3T MR scanner.
  • The lesions were evaluated by measurements of relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF).
  • The Mann-Whitney U test was used to compare rCBV and rCBF measurements of tumor groups -- 13 low-grade and 13 high-grade neuroepithelial (NE) tumors, five metastases, 10 meningiomas, and four others.
  • Peritumoral rCBV and rCBF measurements of high grade NE tumors and metastases were also compared.
  • RESULTS: Measurements of rCBV and rCBF were statistically significantly higher (P < 0.05) in high-grade NE tumors than in low-grade NE tumors.
  • The difference was not statistically significant in comparing high-grade NE tumors with metastases and meningiomas.
  • Peritumoral rCBV of high-grade NE tumors was significantly higher than peritumoral rCBV of metastases (P < 0.05).
  • CONCLUSION: CBV and CBF measurements provided by 3T perfusion MRI can help to predict NE tumor grading preoperatively, and differentiate between primary brain tumors and metastases.
  • [MeSH-major] Brain / blood supply. Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Cerebrovascular Circulation. Image Enhancement / methods. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263367.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


17. Matsuo Y, Kamitani T: Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One; 2010;5(5):e10481
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes.
  • CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi.
  • Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Line, Tumor. Female. Humans. MART-1 Antigen. Male. Melanins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Nevus / metabolism. Nevus / pathology. Pigmentation. Retinoblastoma / metabolism. Retinoblastoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Mar;54(3):196-200 [11253130.001]
  • [Cites] Neurology. 2009 Oct 20;73(16):1286-91 [19841380.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3090-9 [11943812.001]
  • [Cites] Nat Rev Neurosci. 2002 Jul;3(7):531-41 [12094209.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):217-23 [14991540.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] Cancer. 1999 Feb 25;87(1):37-42 [10096358.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):617-27 [10440689.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):201-5 [15583688.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3523-30 [16030137.001]
  • [Cites] Epidemiology. 2006 Sep;17(5):582-7 [16837822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:43 [17980020.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Feb;6(2):105-17 [19107110.001]
  • [Cites] Virchows Arch. 2009 May;454(5):505-11 [19352698.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1792(7):616-24 [18955133.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1039-46 [11474288.001]
  • (PMID = 20463956.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG024497
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanins; 0 / Neoplasm Proteins; 0 / alpha-Synuclein
  • [Other-IDs] NLM/ PMC2864738
  •  go-up   go-down


18. Schneider AB, Ron E, Lubin J, Stovall M, Shore-Freedman E, Tolentino J, Collins BJ: Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck. Neuro Oncol; 2008 Feb;10(1):73-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck.
  • Childhood radiation exposure has been associated with an increased risk for developing several neoplasms, particularly benign and malignant thyroid tumors, but little is known about the risk of developing acoustic neuromas.
  • Forty-three patients developed benign acoustic neuromas, forty of them surgically resected, far in excess of what might be expected from data derived from brain tumor registries.
  • Although acoustic neuromas are usually benign and often asymptomatic, many cause significant morbidity.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):453-9 [16767718.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1555-63 [12381708.001]
  • [Cites] J Neurosurg Sci. 2003 Jun;47(2):113-6; discussion 116 [14618141.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1644-54 [15378499.001]
  • [Cites] Arch Environ Health. 1976 Jan-Feb;31(1):21-8 [1244805.001]
  • [Cites] N Engl J Med. 1976 May 6;294(19):1019-25 [1256510.001]
  • [Cites] JAMA. 1977 May 9;237(19):2098-100 [576893.001]
  • [Cites] Mayo Clin Proc. 1980 Oct;55(10):648-50 [7412405.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2159-63 [6850504.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Jul;63(1):107-12 [3711256.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] N Engl J Med. 1989 Mar 30;320(13):835-40 [2927450.001]
  • [Cites] Br J Cancer. 1989 May;59(5):783-6 [2736213.001]
  • [Cites] Neurosurgery. 1989 Jun;24(6):929-32 [2747873.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Aug;77(2):362-9 [8345040.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):254-7 [7829622.001]
  • [Cites] Arch Intern Med. 1996 Sep 9;156(16):1873-8 [8790083.001]
  • [Cites] Am J Epidemiol. 1996 Oct 15;144(8):728-33 [8857821.001]
  • [Cites] Radiat Res. 1998 Jun;149(6):625-30 [9611101.001]
  • [Cites] J Natl Cancer Inst. 1963 Dec;31:1379-405 [14087657.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5747-53 [16030170.001]
  • [Cites] Am J Clin Oncol. 2005 Dec;28(6):640-1 [16317282.001]
  • [Cites] JAMA. 2006 Jan 25;295(4):416-28 [16434632.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):327-33 [16357108.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3236-41 [12107231.001]
  • (PMID = 18079359.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21518; United States / NCI NIH HHS / CP / N01-CP-85604; United States / NCI NIH HHS / CP / N01-CP-95614; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2600840
  •  go-up   go-down


19. Chahlavi A, Staugaitis SM, Yahya R, Vogelbaum MA: Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma. J Clin Neurosci; 2005 Aug;12(6):720-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma.
  • OBJECTIVE/IMPORTANCE: Cancer metastasis to a pre-existing intracranial tumor is rare, but several cases have been reported.
  • We report an unusual case of a "collision tumor" consisting of a renal cell carcinoma metastasis to an intracranial meningioma.
  • MRI characteristics of the tumor were consistent with meningioma.
  • On octreotide-SPECT and F-18 fluorodeoxyglucose (FDG)-PET scans, the lesion showed octreotide uptake but did not accumulate FDG, both of which are consistent with a diagnosis of benign meningioma.
  • The intracranial tumor was resected, and subacute subdural blood was found overlying a soft, reddish tumor.
  • CONCLUSION: Collision tumor involving metastatic renal cell carcinoma to an intracranial meningioma is a rare occurrence.
  • Diagnosis by non-invasive means, with use of a combination of octreotide-SPECT and FDG-PET may not accurately reflect the malignant component of such a collision tumor.
  • In this case, the collision tumor also demonstrated a propensity to undergo spontaneous hemorrhage.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma / pathology. Kidney Neoplasms / pathology. Meningioma / secondary. Tomography, Emission-Computed, Single-Photon

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115558.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Sarnat HB, Flores-Sarnat L: Embryology of the neural crest: its inductive role in the neurocutaneous syndromes. J Child Neurol; 2005 Aug;20(8):637-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the neurocutaneous syndromes, diverse features result from abnormal neural crest differentiation, providing a more encompassing embryologic basis for these disorders than the traditional view that these syndromes are somehow related to skin and brain because both are ectodermal derivatives.
  • Abnormal angiogenesis, areas of abnormal pigmentation that sometimes follow the lines of Blashko, nerve sheath proliferations, disorders of chromaffin tissue, lipomes and benign and malignant tumors are frequent features.
  • Many defective genes in neurocutaneous syndromes have an additional function as tumor suppressors.
  • The craniofacial abnormalities associated with many cerebral malformations and cutaneous lesions in some neurocutaneous syndromes emphasize an important inductive role of the neural tube in the development of non-neural tissues, mediated through neural crest.

  • MedlinePlus Health Information. consumer health - Craniofacial Abnormalities.
  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225807.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


22. Lee DK, Cho KT, Im SH, Hong SK: Pleomorphic xanthoastrocytoma with an intracystic hemorrhage : a case report and literature review. J Korean Neurosurg Soc; 2007 Nov;42(5):410-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) has been considered as a low grade tumor of adolescents and young adults.
  • Although this tumor often shows cystic component, the hemorrhage within the cyst is extremely rare.
  • After gross total resection of the tumor, the patient was fully recovered from neurological deficit.
  • It is suggested that this typically benign tumor could be presented with hemorrhage, causing a rapid neurological deterioration.
  • Prompt surgical intervention, especially total removal of the tumor can provide an excellent functional recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):269-74 [8293186.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Nov-Dec;14(6):1397-404 [8279337.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):353-5 [1513442.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):1079-82; discussion 1082 [12234421.001]
  • [Cites] Br J Radiol. 2001 Mar;74(879):270-2 [11338106.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):169-71 [15690134.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):154-6 [8770268.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):564-9 [8113873.001]
  • (PMID = 19096580.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588191
  • [Keywords] NOTNLM ; Cyst / Hemorrhage / Mural nodule / Pleomorphic xanthoastrocytoma (PXA)
  •  go-up   go-down


23. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


24. Moliterno JA, Sood S, Zambrano E, Kim JH, Piepmeier JM, Baehring JM: Intracranial benign fibrous histiocytomas: a case report and review. J Neurooncol; 2009 Apr;92(2):203-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial benign fibrous histiocytomas: a case report and review.
  • Although there have been several reports about malignant fibrous histiocytomas, less is known about the benign variant of these intracranial tumors as they are often misclassified as other types of tumors.
  • Pathology revealed benign fibrous histiocytoma.
  • We also review other cases reported in the literature in an effort to provide further insight into the diagnosis and management of this rare tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):215-8 [10682930.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):73-6; discussion 76 [16200478.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Oct;30(10 ):759-62 [1708451.001]
  • [Cites] Clin Neuropathol. 2002 May-Jun;21(3):93-8 [12049182.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):284-93 [7681032.001]
  • [Cites] Acta Neuropathol. 1973 Feb 19;23(3):187-99 [4348056.001]
  • [Cites] Surg Neurol. 1988 Jan;29(1):27-31 [3336836.001]
  • [Cites] No Shinkei Geka. 1984 Apr;12 (5):641-8 [6087179.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):157-60 [11508815.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):9-17 [11131990.001]
  • [Cites] No Shinkei Geka. 1991 Mar;19(3):267-71 [2038418.001]
  • (PMID = 19030779.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


25. Zhang QF, Liu DL, Yang ZQ: [Surgical treatment of tumors in anterior and middle skull base by modified maxillary bone disassembly procedures]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Nov;41(11):840-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of tumors in anterior and middle skull base by modified maxillary bone disassembly procedures].
  • OBJECTIVE: To explore the therapeutic effect of the modified maxillary bone disassembly procedures on patients with tumors in the anterior and middle skull base.
  • Ten tumors in the anterior and middle skull base were resected according to the pathology, size and site of the skull base tumors including 9 benign tumors and 1 malignant tumor.
  • RESULTS: All tumors were resected completely.
  • The patients with benign tumors showed no recurrence .
  • One patient with melanoma died of brain metastase.
  • CONCLUSIONS: It is necessary to estimate the tumors thoroughly before surgery.
  • According to the location of the tumor, the modified maxillary bone disassembly is the nearest and harmless approach, through which the tumors can be completely excised with minimal invasiveness.
  • [MeSH-major] Maxilla / surgery. Skull Base Neoplasms / surgery. Surgery, Oral / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283538.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Lee JH, Sade B, Choi E, Golubic M, Prayson R: Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg; 2006 Jul;105(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors analyzed the relationship between the tumors' histological subtypes and sites of origin in the 731 patients from this group who harbored tumors that were determined to be benign histologically (World Health Organization Grade I).
  • Meningothelial meningiomas (MMs) accounted for 63.5% (464/731) of the Grade I tumors.
  • Analysis of the increasingly available data on genetic and topographic characteristics of MMs suggests that they may represent a unique entity, contrary to the prevailing belief that all benign meningiomas are identical tumors.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Base Neoplasms / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871881.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ito E, Saito K, Nagatani T, Ishiyama J, Terada K, Yoshida M, Wakabayashi T: Intradural cranial chordoma. World Neurosurg; 2010 Mar;73(3):194-7; discussion e31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intradural chordomas are rare and have been considered benign owing to the feasibility of complete resection and the display of lesser aggressive biologic behavior than typical chordomas.
  • A tumor (anti-Ki-67 monoclonal antibody [MIB-1], 13.9%) in a 59-year-old woman was strongly adherent to the brainstem and involved the basilar artery and its branches.
  • After subtotal removal, the remnant tumor was treated with stereotactic radiotherapy.
  • A tumor (MIB-1, 6.2%) in a 75-year-old woman repeatedly recurred even after initial gross total removal.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Chordoma / diagnosis. Chordoma / therapy. Dura Mater

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20860957.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • Thus, EMA was found to be of little value in the diagnosis of ependymoma and in the differentiation between different types and grades.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


29. Wada K, Maruno M, Suzuki T, Kagawa N, Hashiba T, Fujimoto Y, Hashimoto N, Izumoto S, Yoshimine T: Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray. Neurol Res; 2005 Oct;27(7):747-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray.
  • BACKGROUND: Meningioma is the commonest brain tumor and many genetic abnormalities, such as the loss of chromosome 22q and the mutation of NF2, have been reported.
  • METHODS: These classical abnormalities were detected using Southern blot, PCR, fluorescence in situ hybridization and comparative genomic hybridization, but these methods examine only very limited regions or limited mapping resolution of the tumor genome.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197812.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology


31. Shah NC, Ray A, Bartels U, Rutka J, Bouffet E, Drake J, Hawkins CE, Huang A: Diffuse intrinsic brainstem tumors in neonates. Report of two cases. J Neurosurg Pediatr; 2008 May;1(5):382-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intrinsic brainstem tumors in neonates. Report of two cases.
  • The authors report on 2 newborn infants with the unusual presentation of intrinsic brainstem tumors.
  • Intrinsic pontine tumors, characteristically seen in school-age children, are most often high-grade gliomas that are almost invariably fatal.
  • However, the microanatomy and natural history of pontine tumors in neonates are unknown.
  • In one child, postmortem examination revealed a primary brainstem primitive neuroectodermal tumor.
  • The authors conclude that, as in older children, neonatal intrinsic brainstem tumors may be of a highly malignant nature.
  • The rapid tumor progression in both cases indicates that where a diagnostic procedure may pose significant risks, supportive observation can aid in distinguishing malignant from benign tumor growth.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / therapy. Glioma / pathology. Glioma / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Pediatr. 2008 May;1(5):381; discussion 381 [18447672.001]
  • (PMID = 18447673.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Harada M, Ishihara Y, Itoh K, Yamanaka R: Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep; 2007 Mar;17(3):629-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we searched for new target candidates in specific immunotherapy for malignant glioma by utilizing cDNA microarray technology to compare gene expressions in malignant glioma tissues to those in benign glioma and a panel of normal tissues.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Brain Neoplasms / immunology. Glioma / immunology. HLA-A Antigens / immunology. Kinesin / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Cancer Vaccines. Cell Line, Tumor. Gene Expression. Gene Expression Profiling. HLA-A24 Antigen. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunotherapy / methods. Oligonucleotide Array Sequence Analysis. Peptides / immunology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273744.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A24 Antigen; 0 / Immunoglobulin G; 0 / Peptides; 0 / RNA, Messenger; EC 3.6.1.- / Kinesin
  •  go-up   go-down


33. Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M: Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol; 2006;45(7):796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staging procedures were thoracic and abdominal CT-scan, FDG-PET and CT or MRI of the brain in all patients.
  • Clinical target volume was the tumor as seen in lung windowing of CT and in FDG-PET.
  • We observed four (6%) local tumor recurrences, resulting in an actuarial local tumor control rate of 96%, 88% and 88% after 1, 2 and 3 year follow-up.
  • Nineteen patients died, with eight patients due to cancer (12%), two to local tumor progression alone.
  • Late effects were pneumonitis III degrees in 1%, rib fractures in 3%, and benign pleural effusion in 2 patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Dose Fractionation. Lung Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Fluorodeoxyglucose F18. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography / methods. Radiation Injuries / diagnosis. Radiation Injuries / epidemiology. Radiotherapy Dosage. Survival Analysis


34. Samadi N, Ahmadi SA: Meningioma: a clinicopathological evaluation. Malays J Med Sci; 2007 Jan;14(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 205(86.1%) cases were benign, 19(8%) atypical and 14(5.9%) malignant.
  • 181(18%) cases were primary and 51(27%) secondary; 35(68%) of the latter benign, 7(14%) atypical and 9(18%) malignant.
  • All intraspinal meningiomas were benign.
  • In benign cranial and spinal types female to male ratios were 1.9: 1 and 1.3: 1 ; while in atypical and malignant types were 1 :1.4 and 1:3.1 respectively.
  • Mean ages were 49.9 for benign.
  • The most frequent site of involvement in all grades of intracranial tumors was cerebral convexity (31.1 %).
  • Female preponderance seen in benign nonrecurrent meningioma became increasingly less prominent and even reversed in recurrent, atypical and malignant forms.
  • Benign recurrent tumors were similar to non-recurrent tumors microscopically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Cutan Pathol. 1994 Dec;21(6):549-56 [7699122.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):562-9 [9488313.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):841-6 [1479598.001]
  • (PMID = 22593651.001).
  • [ISSN] 1394-195X
  • [Journal-full-title] The Malaysian journal of medical sciences : MJMS
  • [ISO-abbreviation] Malays J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3351217
  • [Keywords] NOTNLM ; Mahmood grading system / WHO grading system / brain tumor / intracranial / intraspinal / meningioma
  •  go-up   go-down


35. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


36. Distelmaier F, Fahsold R, Reifenberger G, Messing-Juenger M, Schaper J, Schneider DT, Göbel U, Mayatepek E, Rosenbaum T: Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Childs Nerv Syst; 2007 Mar;23(3):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DISCUSSION: The girl's death 3 days after diagnosis of the brain tumor exemplifies that NF1 still is a life-threatening disease despite its generally benign course in most patients.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Mutation, Missense. Neurofibromatosis 1 / complications. Neurofibromin 1 / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Am J Hum Genet. 1993 Aug;53(2):305-13 [8328449.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):63-6 [8021787.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1699-702 [16033085.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):107-12 [12784876.001]
  • [Cites] Am J Med Genet A. 2004 Jun 15;127A(3):224-9 [15150770.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Childs Nerv Syst. 1993 Dec;9(8):448-51 [8124670.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):236-45 [15665300.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Pediatrics. 1999 Oct;104(4):e49 [10506274.001]
  • [Cites] J Med Genet. 1999 Dec;36(12):893-6 [10593996.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(11):1085-7 [9442225.001]
  • [Cites] Pediatrics. 1995 Aug;96(2 Pt 1):368-72 [7630704.001]
  • [Cites] Pediatr Radiol. 1991;21(6):389-94 [1749666.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • (PMID = 17009007.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neurofibromin 1
  •  go-up   go-down


37. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


38. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A: Molecular signatures define two main classes of meningiomas. Mol Cancer; 2007;6:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningiomas are common brain tumors that are classified into three World Health Organization grades (benign, atypical and malignant) and are molecularly ill-defined tumors.
  • While all benign meningiomas fall into the low-proliferative group and all malignant meningiomas fall into the high-proliferative group, atypical meningiomas distribute into either one of these groups.
  • We have identified genes that distinguish benign low-proliferative meningiomas from malignant high-proliferative meningiomas and have found that gain of cell-proliferation markers and loss of components of the transforming growth factor-beta signaling pathway were the major molecular mechanisms that distinguish these two groups.
  • CONCLUSION: Collectively, our data suggests that atypical meningiomas are not a molecularly distinct group but are similar to either benign or malignant meningiomas.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / classification. Meningeal Neoplasms / genetics. Meningioma / classification. Meningioma / genetics. Nucleic Acid Hybridization / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):445-54 [16772868.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2907-18 [15837741.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):360-8 [1328762.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] Genome Biol. 2003;4(1):R7 [12540299.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Genome Res. 2002 Feb;12(2):325-32 [11827952.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 17937814.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2173907
  •  go-up   go-down


39. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I: iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res; 2008 Mar;7(3):897-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential expression of brain creatine kinase (CKBB), soluble catechol-O-methyltransferase (S-COMT), tumor rejection antigen (gp96), and glucose regulated protein, 78 kDa (grp78), was confirmed by Western blotting or independent 2D-PAGE analysis.
  • The clinical relevance of gp96 was assessed by immunohistochemistry using prostate tissues from benign ( n = 95), malignant ( n = 66), and metastatic cases ( n = 3).
  • Benign epithelium showed absent/weak gp96 expression in the basal cells, in contrast to the moderate/strong expression seen in malignant epithelium.
  • Furthermore, there was a statistically significant difference in the intensity of gp96 expression between benign and malignant cases ( p < 0.0005, Mann-Whitney U).
  • [MeSH-major] Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism. Proteomics
  • [MeSH-minor] Cell Line, Tumor. Chromatography, Liquid. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Male. Reproducibility of Results. Spectrometry, Mass, Electrospray Ionization / methods


40. Zafrakas M, Chorovicer M, Klaman I, Kristiansen G, Wild PJ, Heindrichs U, Knüchel R, Dahl E: Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int J Cancer; 2006 Mar 15;118(6):1453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GABRP is located on chromosome 5q34 and it encodes the pi-subunit of the gamma-aminobutyric acid (GABA) receptor, a transmembrane protein expressed in the brain and several nonneuronal tissues.
  • GABRP downregulation in breast cancer was confirmed by quantitative RT-PCR in cryopreserved breast tumour and normal breast tissue specimens (n = 22), in archival formalin-fixed, paraffin-embedded tissue specimens (n = 32), as well as in breast cancer cell lines (n = 8).
  • Non-radioisotopic ISH showed strong GABRP expression in normal epithelial and benign papilloma breast cells, but no signal could be detected in invasive ductal carcinoma.
  • Altogether, these data suggest that GABRP is progressively down-regulated with tumour-progression, and that it may be useful as a prognostic marker in breast cancer.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / genetics. Protein Subunits / genetics. Receptors, GABA-A / genetics
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization / methods. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction


41. Hasegawa M, Fujisawa H, Hayashi Y, Yamashita J, Suzuki M, Matsui O: CT arteriography for orbital tumors: diagnostic and surgical value. J Clin Neurosci; 2005 Jun;12(5):548-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT arteriography for orbital tumors: diagnostic and surgical value.
  • The aim of this study is to investigate the efficacy of dynamic computed tomography (CT) during selective angiography (CT-arteriography) of orbital tumors in the evaluation of intratumoral vascular anatomy, feeding artery territory, and histological diagnosis.
  • Among 35 consecutive cases with various orbital lesions, those cases showing tumor staining or pooling of the contrast medium on digital subtraction angiography (DSA) were evaluated by CT-arteriography (n = 14).
  • Patterns of CT-arteriography were categorized into three subgroups: homogeneous enhancement (benign lymphoid lesion), partial enhancement (schwannomas and carcinomas), and patchy multinodular enhancement (specific for cavernous angiomas).
  • CT-arteriography, with a minimal dose of contrast medium, can offer significant advantages over intravenously injected dynamic neuroimaging, and provides additional valuable preoperative information about the orbital tumor under investigation.
  • [MeSH-major] Ophthalmic Artery / pathology. Ophthalmic Artery / radiography. Orbit / pathology. Orbit / radiography. Orbital Neoplasms / blood supply. Orbital Neoplasms / radiography. Tomography, X-Ray Computed / trends
  • [MeSH-minor] Adult. Aged. Angiography / methods. Angiography / trends. Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Brain Neoplasms / radiography. Carcinoma / blood supply. Carcinoma / pathology. Carcinoma / radiography. Contrast Media / standards. Diagnosis, Differential. Female. Hemangioma, Cavernous / blood supply. Hemangioma, Cavernous / pathology. Hemangioma, Cavernous / radiography. Humans. Lacrimal Apparatus / blood supply. Lacrimal Apparatus / pathology. Lacrimal Apparatus / radiography. Male. Middle Aged. Neurilemmoma / blood supply. Neurilemmoma / pathology. Neurilemmoma / radiography. Optic Nerve Neoplasms / blood supply. Optic Nerve Neoplasms / pathology. Optic Nerve Neoplasms / radiography. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982890.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


42. Bodack MI: Ptosis and cranial nerve IV palsy reveal juvenile myasthenia gravis. Optometry; 2009 Jul;80(7):342-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both cases, these conditions can be benign and require no further workup.
  • If a patient presents with multiple neurologic signs, a sudden onset eye turn, or ptosis, the patient must undergo a workup to rule out a pathologic etiology, specifically a brain tumor.
  • If the results of the neuroimaging are normal, and the findings are variable, myasthenia gravis should be considered, and additional testing should be ordered to assist in the diagnosis.
  • Diagnosis of myasthenia gravis was made based on clinical presentation and response to ice pack testing.
  • CONCLUSIONS: Although rare, myasthenia should be considered a diagnosis in children who present with variable ptosis or strabismus.
  • [MeSH-major] Blepharoptosis / etiology. Myasthenia Gravis / complications. Myasthenia Gravis / diagnosis. Strabismus / etiology. Trochlear Nerve Diseases / etiology
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neurology. Optometry. Referral and Consultation

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • Genetic Alliance. consumer health - Ptosis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Optometry. 2009 Sep;80(9):466
  • (PMID = 19545846.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E: Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding? J Neurosurg; 2009 Sep;111(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.
  • Although unusual, malignant transformation with leptomeningeal seeding into the brain or spinal cord may occur years after the initial diagnosis.
  • The authors report a unique case of multifocal benign meningeal melanocytoma involving both cerebellopontine angles and the thoracic spinal cord, with associated diffuse leptomeningeal hyperpigmentation.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361258.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM: Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun; 2008 Aug;22(6):890-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adaptive immune response of ovarian cancer patients has been linked to survival, and is known to be impaired in the tumor microenvironment.
  • Thirty-seven patients with epithelial ovarian cancer and 14 patients with benign ovarian neoplasms completed psychosocial questionnaires pre-surgery.
  • Lymphocytes from peripheral blood, tumor, and ascites (fluid around the tumor), were obtained on the day of surgery.
  • Expression of the Type-1 cytokine interferon-gamma (IFN gamma), and the Type-2 cytokine interleukin-4 (IL-4) by T-helper (CD4(+)) and T-cytotoxic (CD8(+)) cells was measured under autologous tumor-stimulated, polyclonally-stimulated, or unstimulated conditions.
  • Among cancer patients, marked elevations in unstimulated and tumor-stimulated Type-2 responses were seen, particularly in ascites and tumor-infiltrating lymphocytes (P values<0.01).
  • Although effects of polyclonal stimulation should be generalized with caution to the in vivo immune response, findings suggest that depressed and anxious mood are associated with greater impairment of adaptive immunity in peripheral blood and in the tumor microenvironment among ovarian cancer patients.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1327-35 [9815928.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):83-107 [9450372.001]
  • [Cites] J Formos Med Assoc. 1999 Jan;98(1):24-30 [10063270.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6671-80 [10352285.001]
  • [Cites] Cancer Immunol Immunother. 1999 May-Jun;48(2-3):147-52 [10414469.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):1923-8 [10438927.001]
  • [Cites] Adv Exp Med Biol. 1999;461:1-24 [10442164.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2492-9 [10452985.001]
  • [Cites] J Exp Med. 1999 Sep 6;190(5):617-27 [10477547.001]
  • [Cites] J Psychosom Res. 2004 Oct;57(4):353-8 [15518669.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1598-605 [15547530.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):590-6 [15699022.001]
  • [Cites] Psychosom Med. 2005 Jul-Aug;67(4):638-42 [16046380.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):571-80 [16397274.001]
  • [Cites] Brain Behav Immun. 2007 Feb;21(2):185-94 [16908118.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):374-83 [17360153.001]
  • [Cites] Springer Semin Immunopathol. 1999;21(3):231-48 [10666771.001]
  • [Cites] J Consult Clin Psychol. 2000 Feb;68(1):31-45 [10710838.001]
  • [Cites] Ann Behav Med. 2000 Winter;22(1):29-37 [10892526.001]
  • [Cites] Nat Med. 2001 Feb;7(2):206-14 [11175852.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:94-105 [11268424.001]
  • [Cites] Surgery. 2001 Jun;129(6):749-56 [11391375.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):654-8 [11402277.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Aug;56(8):M477-82 [11487599.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6497-502 [11714817.001]
  • [Cites] Brain Behav Immun. 2002 Feb;16(1):1-16 [11846437.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):387-93 [12566422.001]
  • [Cites] Brain Behav Immun. 2003 Apr;17(2):69-85 [12676570.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6784-90 [14583474.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):64-75 [14764031.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):1-8 [14987957.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5467-77 [15100288.001]
  • [Cites] Psychol Bull. 2004 Jul;130(4):601-30 [15250815.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1024:138-46 [15265778.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3570-80 [15337807.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):617-25 [15465465.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1133-9 [7193084.001]
  • [Cites] J Pers Assess. 1983 Jun;47(3):305-6 [6886962.001]
  • [Cites] Obstet Gynecol. 1984 Nov;64(5):708-14 [6493663.001]
  • [Cites] Mol Pharmacol. 1987 Apr;31(4):377-84 [3033466.001]
  • [Cites] J Consult Clin Psychol. 1989 Dec;57(6):683-91 [2600238.001]
  • [Cites] J Immunol. 1990 Mar 15;144(6):2211-5 [1968925.001]
  • [Cites] J Immunol. 1991 Mar 1;146(5):1700-7 [1704404.001]
  • [Cites] Immunol Lett. 1991 Sep;30(1):141-2 [1683651.001]
  • [Cites] JAMA. 1992 Mar 4;267(9):1244-52 [1538563.001]
  • [Cites] Gynecol Obstet Invest. 1993;35(2):118-20 [8383627.001]
  • [Cites] Brain Behav Immun. 1993 Jun;7(2):154-63 [8394164.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):429-37 [8123759.001]
  • [Cites] Proc Assoc Am Physicians. 1996 Sep;108(5):374-81 [8902882.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):276-84 [8903466.001]
  • [Cites] J Allergy Clin Immunol. 1996 Dec;98(6 Pt 2):S161-73 [8977524.001]
  • [Cites] Cell Immunol. 1997 Feb 1;175(2):150-6 [9023420.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):30-6 [9428780.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • (PMID = 18276105.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104825-01; United States / NCI NIH HHS / CA / R21CA88293; United States / NCI NIH HHS / CA / R01CA104825; United States / NCI NIH HHS / CA / R01 CA104825; United States / NCI NIH HHS / CA / R21 CA088293-01; United States / NCI NIH HHS / CA / CA088293-01; United States / NCI NIH HHS / CA / R21 CA088293; United States / NCI NIH HHS / CA / R01 CA104825-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon Type I; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ NIHMS59847; NLM/ PMC2605940
  •  go-up   go-down


45. Myung SK, Ju W, McDonnell DD, Lee YJ, Kazinets G, Cheng CT, Moskowitz JM: Mobile phone use and risk of tumors: a meta-analysis. J Clin Oncol; 2009 Nov 20;27(33):5565-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobile phone use and risk of tumors: a meta-analysis.
  • PURPOSE: Case-control studies have reported inconsistent findings regarding the association between mobile phone use and tumor risk.
  • Compared with never or rarely having used a mobile phone, the odds ratio for overall use was 0.98 for malignant and benign tumors (95% CI, 0.89 to 1.07) in a random-effects meta-analysis of all 23 studies.
  • Mobile phone use of 10 years or longer was associated with a risk of tumors in 13 studies reporting this association (odds ratio = 1.18; 95% CI, 1.04 to 1.34).
  • CONCLUSION: The current study found that there is possible evidence linking mobile phone use to an increased risk of tumors from a meta-analysis of low-biased case-control studies.
  • [MeSH-major] Cell Phones / utilization. Neoplasms / epidemiology. Neoplasms / etiology
  • [MeSH-minor] Brain Neoplasms / epidemiology. Brain Neoplasms / etiology. Brain Neoplasms / physiopathology. Case-Control Studies. Female. Follow-Up Studies. Humans. Incidence. Korea. Male. Risk Assessment. Sensitivity and Specificity. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Mar 1;28(7):e121 [20100952.001]
  • [CommentIn] J Clin Oncol. 2010 Mar 1;28(7):e122; author reply e124-5 [20100950.001]
  • [CommentIn] J Clin Oncol. 2010 Mar 1;28(7):e123; author reply e124-5 [20100944.001]
  • (PMID = 19826127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / U48/DP000033
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


46. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Lakhan SE, Harle L: Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature. J Med Case Rep; 2009;3:87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficult diagnosis of brainstem glioblastoma multiforme in a woman: a case report and review of the literature.
  • The diagnosis of a high-grade brainstem glioma is usually reached due to the presentation of rapidly progressing brainstem, cranial nerve and cerebellar symptoms.
  • At autopsy, a high-grade invasive pontine tumor was identified.
  • While radiographic findings are often suggestive of the underlying pathology, this case represents the possibility of glioblastoma multiforme presenting as a deceptively benign appearing lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Cancer. 2004 Oct-Dec;41(4):170-4 [15659871.001]
  • [Cites] Pediatr Radiol. 1998 Aug;28(8):575-9 [9716624.001]
  • [Cites] No To Shinkei. 1997 Jun;49(6):547-51 [9198096.001]
  • [Cites] J Med Assoc Thai. 1996 Jun;79(6):403-8 [8855617.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):24-34 [8817612.001]
  • [Cites] Pediatr Radiol. 2006 Sep;36(9):959-64 [16847598.001]
  • [Cites] Neurosurg Clin N Am. 1993 Jul;4(3):529-36 [8353450.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1294-6 [6277461.001]
  • [Cites] Acta Neurochir (Wien). 2002 Sep;144(9):941-4; discussion 944-5 [12376778.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] CA Cancer J Clin. 1993 Sep-Oct;43(5):272-88 [8364769.001]
  • (PMID = 19946563.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783086
  •  go-up   go-down


48. Karbowniczek M, Zitserman D, Khabibullin D, Hartman T, Yu J, Morrison T, Nicolas E, Squillace R, Roegiers F, Henske EP: The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest; 2010 Jan;120(1):93-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in either of the genes encoding the tuberous sclerosis complex (TSC), TSC1 and TSC2, result in a multisystem tumor disorder characterized by lesions with unusual lineage expression patterns.
  • In human angiomyolipomas, benign renal neoplasms often found in tuberous sclerosis patients, we found evidence of Notch receptor cleavage and Notch target gene activation.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1999 Oct 22;53(7):1384-90 [10534239.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Cell. 2000 May 26;101(5):499-510 [10850492.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):58-67 [11146627.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):50-7 [11146626.001]
  • [Cites] Cell. 2001 May 4;105(3):345-55 [11348591.001]
  • [Cites] Cell. 2001 May 4;105(3):357-68 [11348592.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1383-92 [11390358.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14469-74 [11734647.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Genes Dev. 2002 Oct 15;16(20):2627-32 [12381661.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):491-500 [12547707.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):326-30 [12629552.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):559-65 [12766775.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):566-71 [12766776.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):578-81 [12771962.001]
  • [Cites] Clin Neuropathol. 2003 May-Jun;22(3):119-28 [12809354.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1457-66 [12820960.001]
  • [Cites] J Soc Biol. 2003;197(1):17-22 [12868262.001]
  • [Cites] Genes Dev. 2003 Aug 1;17(15):1829-34 [12869586.001]
  • [Cites] Development. 2006 Sep;133(17):3277-82 [16908627.001]
  • [Cites] J Biol Chem. 2006 Sep 1;281(35):25447-56 [16803888.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):217-28 [18079963.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Differentiation. 2008 Jul;76(6):699-716 [18565101.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):8023-32 [19150980.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1259-68 [12906785.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32493-6 [12842888.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700 [12922981.001]
  • [Cites] Curr Opin Cell Biol. 2004 Apr;16(2):195-205 [15196564.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29930-7 [15150271.001]
  • [Cites] Cell. 2004 Oct 1;119(1):87-96 [15454083.001]
  • [Cites] Development. 1993 Jun;118(2):401-15 [8223268.001]
  • [Cites] J Neurosci. 1997 Feb 15;17(4):1425-34 [9006984.001]
  • [Cites] Prog Clin Biol Res. 1997;396:205-15 [9108599.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] Cell. 1999 Feb 19;96(4):529-39 [10052455.001]
  • [Cites] Neuron. 1999 Mar;22(3):451-61 [10197526.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Development. 1999 Aug;126(16):3573-84 [10409503.001]
  • [Cites] J Biochem. 2005 Mar;137(3):423-30 [15809346.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1321-6 [16136513.001]
  • [Cites] Cell. 2005 Sep 9;122(5):763-73 [16137758.001]
  • [CommentIn] J Clin Invest. 2010 Jan;120(1):84-7 [20038806.001]
  • (PMID = 20038815.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS059971; United States / NIDDK NIH HHS / DK / R29 DK051052; United States / NINDS NIH HHS / NS / R56 NS059971; United States / NHLBI NIH HHS / HL / HL81147; United States / NIDDK NIH HHS / DK / R01 DK51052; United States / NHLBI NIH HHS / HL / R01 HL081147; United States / NIDDK NIH HHS / DK / R01 DK051052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Drosophila Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Neuropeptides; 0 / Receptors, Notch; 0 / Rheb protein, Drosophila; 0 / TSC1 protein, Drosophila; 0 / delta protein; 0 / gig protein, Drosophila; 0 / notch protein, Drosophila; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2798691
  •  go-up   go-down


49. Goutagny S, Kalamarides M: Meningiomas and neurofibromatosis. J Neurooncol; 2010 Sep;99(3):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 2 (NF2) is a rare genetic disorder predisposing to multiple benign tumors of the nervous system.
  • Whether meningiomas are part of the schwannomatosis tumor phenotype or not remains debated.
  • Thus, knowledge of tumor behavior is essential in slow growing tumors like meningiomas, to balance the risk of treatment against the natural history of the disease, and to evaluate the efficiency of alternative therapeutics (radiation therapy or new drugs).
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neurofibromatoses / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5032-5039 [19671848.001]
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):208-13 [18687535.001]
  • [Cites] Neuropediatrics. 2005 Feb;36(1):21-34 [15776319.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):610-4 [9322850.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Neurology. 1993 Oct;43(10):2096-8 [8413972.001]
  • [Cites] J Med Genet. 2003 Feb;40(2):109-14 [12566519.001]
  • [Cites] J Med Genet. 2002 May;39(5):315-22 [12011146.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] Neurogenetics. 2010 Feb;11(1):73-80 [19582488.001]
  • [Cites] BMC Med Genomics. 2009 Jul 09;2:42 [19589153.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] J Med Genet. 2005 Jan;42(1):45-8 [15635074.001]
  • [Cites] Arch Ophthalmol. 2007 Mar;125(3):389-94 [17353411.001]
  • [Cites] Neurosurgery. 2007 Mar;60(3):460-8; discussion 468-70 [17327790.001]
  • [Cites] Am J Med Genet A. 2010 Feb;152A(2):327-32 [20082463.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] Rev Neurol (Paris). 2005 Mar;161(3):275-83 [15800448.001]
  • [Cites] J Med Genet. 2010 Aug;47(8):567-8 [20472658.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):504-12 [10850863.001]
  • [Cites] J Neurosurg. 2009 Sep;111(3):458-63 [19199473.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):489-95 [16383246.001]
  • [Cites] Clin Genet. 2007 Apr;71(4):354-8 [17470137.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1068-1077 [16765675.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):562-9 [9488313.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Arch Dis Child. 1999 Dec;81(6):496-9 [10569966.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Neurology. 1996 Apr;46(4):1072-9 [8780094.001]
  • [Cites] Am J Hum Genet. 1998 Sep;63(3):727-36 [9718334.001]
  • [Cites] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):705-9 [7674021.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]
  • [Cites] Br J Ophthalmol. 1992 May;76(5):310-2 [1390517.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Clin Genet. 2008 Oct;74(4):358-66 [18647326.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):447-53 [8113857.001]
  • (PMID = 20714782.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


50. Cohen-Gadol AA, Geryk B, Binder DK, Tubbs RS: Conquering the third ventricular chamber. J Neurosurg; 2009 Sep;111(3):590-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors have reviewed the previously undisclosed efforts of Cushing to approach the third ventricle through a direct review of his available patient records at the Cushing Brain Tumor Registry.
  • The authors compare these efforts to those of Dandy published in Dandy's pioneering work Benign Tumors in the Third Ventricle of the Brain: Diagnosis and Treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 May;112(5):1156-61; author reply 1161 [20345221.001]
  • (PMID = 19361257.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Biography; Case Reports; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Cushing H; Dandy W
  •  go-up   go-down


51. Spurlock G, Griffiths S, Uff J, Upadhyaya M: Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer; 2007;6(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.
  • We have carried out NF1 gene mutation analysis on DNA isolated from 25 tumours (dermal and plexiform neurofibromas, malignant peripheral nerve sheath tumour, MPNST), obtained at post-mortem from an NF1 patient.
  • Of the 25 tumours studied from this patient, characterised somatic mutations were identified in 9 tumours, these were six small deletions (748del T, 2534-2557 del 24bp, 2843delA, 3047-3048 del GT, 4743del G, 7720-7721 delAA), an insertion 649 ins 73 bp, a non-sense mutation R1513X and a single splice site mutation, IVS4C-1 G>A, eight of these represent novel sequence changes in the gene.
  • Each of the tumours analysed contained a different somatic NF1 mutation, indicating that each tumour is the result of an independent somatic event.
  • [MeSH-major] Mutation / genetics. Neoplasms / genetics. Neoplasms / pathology. Neurofibromin 1 / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. Base Sequence. Child, Preschool. Chromatography, High Pressure Liquid. Exons / genetics. Gene Deletion. Humans. Microsatellite Instability. Molecular Sequence Data. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):893-904 [16830335.001]
  • [Cites] Hum Genet. 2003 Feb;112(2):117-23 [12522551.001]
  • [Cites] Hum Mutat. 2003 Dec;22(6):423-7 [14635100.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):393-401 [10677298.001]
  • [Cites] Hum Genet. 2001 May;108(5):416-29 [11409870.001]
  • [Cites] Am J Med Genet. 1997 May 16;70(2):138-43 [9128932.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):111-6 [14722914.001]
  • [Cites] Acta Derm Venereol. 1995 Mar;75(2):136-40 [7604643.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Hum Mutat. 2006 Oct;27(10 ):1030-40 [16941471.001]
  • [Cites] Hum Mutat. 1997;9(5):458-64 [9143927.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12 ):e57 [12060695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):346-50 [9177273.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):65-9 [10459349.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):44-9 [10633134.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Am J Hum Genet. 1994 Mar;54(3):424-36 [8116612.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):110-2 [8782831.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1387-92 [11440991.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • (PMID = 17551851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


52. Bricaire C, Plu-Bureau G: [Difficult contraceptions]. Rev Prat; 2008 Jan 15;58(1):55-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, we will address the issues faced in patients with neurological diseases (epilepsy, brain tumor, migraine, prolactin-secreting adenoma), vascular diseases (venous thrombosis, biological thrombophilia, arterial diseases), metabolic disorders (obesity, dyslipemias, diabetes), uterine diseases (fibromas, endometriosis), renal failure, benign and malignant breast diseases as well as in HIV-positive women.

  • MedlinePlus Health Information. consumer health - Birth Control.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326363.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 22
  •  go-up   go-down


53. Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL: Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther; 2009 Dec;16(12):1477-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In benign prostate tissues, G207 and G47Delta titers were notably reduced, whereas strain F titers were maintained at similar levels compared with prostate cancer specimens.

  • Genetic Alliance. consumer health - Prostate cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Apr;74(8):3832-41 [10729157.001]
  • [Cites] Nat Rev Microbiol. 2008 Jul;6(7):529-40 [18552863.001]
  • [Cites] Urology. 2000 Jul;56(1):160-6 [10869659.001]
  • [Cites] Rev Med Virol. 2000 Sep-Oct;10(5):305-19 [11015742.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5714-22 [11059765.001]
  • [Cites] Hum Gene Ther. 2000 Dec 10;11(18):2465-72 [11119418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401 [11353831.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):999-1010 [11387063.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):451-6 [11687957.001]
  • [Cites] Dev Biol. 2004 Mar 15;267(2):387-98 [15013801.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5199-207 [7693334.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] J Virol. 1997 Aug;71(8):6049-54 [9223497.001]
  • [Cites] J Virol. 1998 Sep;72(9):7005-11 [9696792.001]
  • [Cites] J Virol. 1998 Sep;72(9):7064-74 [9696799.001]
  • [Cites] Hum Gene Ther. 1999 Sep 1;10(13):2237-43 [10498254.001]
  • [Cites] Gene Ther. 1999 Oct;6(10):1751-8 [10516725.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1532-40 [15735042.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1257-68 [15824085.001]
  • [Cites] Cancer Gene Ther. 2006 Mar;13(3):253-65 [16179929.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1193-5 [16879022.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):103-13 [17164781.001]
  • [Cites] J Virol. 2007 Apr;81(7):3455-64 [17229694.001]
  • [Cites] J Virol. 2008 Jan;82(2):999-1010 [17977977.001]
  • [Cites] FASEB J. 2008 Jun;22(6):1839-48 [18234972.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • (PMID = 19693098.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102139-06A1; United States / NCI NIH HHS / CA / R01 CA102139; United States / NCI NIH HHS / CA / R01 CA102139-06A1
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS180783; NLM/ PMC2836587
  •  go-up   go-down


54. Maes L, Kalala JP, Cornelissen M, de Ridder L: Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif; 2007 Feb;40(1):14-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By verifying the proliferation capacity, human telomerase reverse transcriptase (hTERT) expression and in vitro invasion, in a group of highly malignant glioblastomas, benign meningiomas and astrocytomas, at the initial stage of progression, we have analysed putative progression in vitro for proliferation and telomerase expression.
  • MATERIALS AND METHODS: The relative proliferation status (visualized with Ki-67 antibodies) and presence of hTERT protein was analysed in 27 intracranial tumours (6 astrocytomas, 8 glioblastomas and 13 meningiomas) by immunohistochemistry on paraffin-embedded biopsy tissue, as well as on primary tumour-derived cell cultures.
  • The group of benign meningiomas had a labelling index of 2.2 (SD = 2.7).
  • The group of benign meningiomas had a labelling index of 12.4 (SD = 19.2) for hTERT.
  • No difference was seen between the group of invasive and non-invasive tumour-derived cell cultures for the histopathological markers Ki-67 and hTERT (P > 0.05) in vitro.
  • CONCLUSIONS: The elevated expression of hTERT and Ki-67 in vitro provides a potential prognostic tool for early detection of the progression of brain tumours.
  • As tumour cells require telomerase for continued proliferation, the expression of hTERT may mark immortality, leading to indefinite life span.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Proliferation. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Telomerase / analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227292.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


55. Zhou LF, Mao Y, Zhang R: Surgical treatment of dumbbell-shaped neurinomas: report of an experience with 57 cases in a single hospital. Surg Neurol; 2007 Dec;68(6):594-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dumbbell-shaped trigeminal neurinomas are rare benign tumors with a controversy regarding their treatment and surgical approaches.
  • METHODS: One hundred thirty-seven patients with trigeminal neurinomas, accounting for 0.6% of all intracranial tumors and 3.8% of intracranial neurinomas, were screened out from the data bank on brain tumors in Hua Shan Hospital (Shanghai, China) from 1978 to 2003.
  • After the tumor in the middle cranial fossa was resected, the tumor in the posterior fossa was resected via a suboccipital approach in the early group and through enlarged porus trigeminus without resection of the petrous apex in the latter group.
  • RESULTS: There were 12 patients in the early group and 45 patients (including 6 patients with recurrent tumors) in the latter group.
  • Tumor size measured on MRI and/or CT were 30 to 40 mm in 4 (33%) cases from the early group and 14 (31%) cases from the latter group, 41 to 50 mm in 8 (67%) cases from the early group and 25 (56%) cases from the latter group, and more than 50 mm in 6 (13%) cases from the latter group.
  • There were 3 patients in the latter group with a tumor extending into the infratemporal fossa and pterygopalatine fossa.
  • Total tumor resection was achieved in 42% (5/12) of the early group and 87% (39/45) of the latter group (chi(2) = 10.897, P < .001); incomplete tumor removal was done in 58% (7/12) of the early group and 13% (6/45) of the latter group.
  • Recurrent tumors occurred in 3 patients from the early group and were reoperated on.
  • One patient with a recurrent tumor from the latter group underwent radiosurgery 5 years after the operation.
  • It is not necessary to resect the petrous apex for removal of the tumor in the posterior fossa.
  • Radiosurgery can be used for the residual or recurrent tumors.
  • [MeSH-major] Cranial Nerve Neoplasms / pathology. Cranial Nerve Neoplasms / surgery. Neurilemmoma / pathology. Neurilemmoma / surgery. Trigeminal Nerve / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053854.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Pui MH, Wang Y: Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children. Clin Imaging; 2005 May-Jun;29(3):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children.
  • The purpose of this study was to determine the efficacy of diffusion-weighted imaging (DWI) and magnetization transfer imaging (MTI) in the differential diagnosis of brain infarct, infection, hamartoma, and tumor in 106 children.
  • There was an inverse relationship between ADC and MTR in subacute/chronic infarct, infection, hamartoma, arachnoid cyst, and tumor relative to normal brain parenchyma.
  • DWI and MTI had a complementary role in the differential diagnosis of acute infarct from infection with lower MTR, from hamartoma with higher ADC, and from low-grade gliomas and benign tumors that had higher ADCs and lower MTRs.
  • ADCs increased and MTRs decreased with the duration of infarct and lower tumor grade.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Central Nervous System Infections / diagnosis. Cerebral Infarction / diagnosis. Diffusion Magnetic Resonance Imaging. Image Processing, Computer-Assisted
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855060.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Jacquin A, Béjot Y, Hervieu M, Biotti D, Caillier M, Ricolfi FC, Moreau T, Giroud M: [Rupture of intracranial dermoid cyst with disseminated lipid droplets]. Rev Neurol (Paris); 2010 Apr;166(4):451-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Dissémination sous-arachnoïdienne de gouttelettes lipidiques par rupture d'un kyste dermoïde intracérébral.
  • INTRODUCTION: Dermoid cysts are rare slow-growing benign tumors of the central nervous system generally diagnosed in the third to fifth decade.
  • CASE REPORTS: We report two cases of ruptured intracranial dermoid tumor with non-specific clinical presentations.
  • The first rupture was asymptomatic and discovered on brain magnetic resonance imaging (MRI) performed for other purposes.
  • The second case was identified on brain imaging performed because of daily headache.
  • Monitoring with brain MRI can be sufficient if the rupture has no severe clinical impact.
  • [MeSH-major] Brain Neoplasms / pathology. Dermoid Cyst / pathology. Lipid Metabolism / physiology
  • [MeSH-minor] Adult. Brain / pathology. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Rupture. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19846186.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


58. Sampetrean O, Maehara T, Arai N, Nemoto T: Rapidly growing dysembryoplastic neuroepithelial tumor: case report. Neurosurgery; 2006 Dec;59(6):E1337-8; discussion E1338
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing dysembryoplastic neuroepithelial tumor: case report.
  • OBJECTIVE: During the past 15 years, the concept of dysembryoplastic neuroepithelial tumors has continued to evolve.
  • We present an interesting case of dysembryoplastic neuroepithelial tumor that showed rapid growth during a short period of time.
  • INTERVENTION: A combined tumor removal and epileptogenic focus resection surgery was performed immediately.
  • In the pathological examination, the presence of the specific glioneuronal element with a Ki-67 labeling index of lower than 1%, as well as the glial component with a Ki-67 labeling index of 8%, led to a postoperative diagnosis of dysembryoplastic neuroepithelial tumor, complex form.
  • CONCLUSION: The lesion did not behave as a stable benign entity as it is generally accepted, and is, therefore, presented as an argument in favor of an early and complete resection.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasms, Neuroepithelial / pathology. Neoplasms, Neuroepithelial / surgery. Temporal Lobe / pathology. Temporal Lobe / surgery. Teratoma / pathology. Teratoma / surgery
  • [MeSH-minor] Child. Humans. Male. Seizures / diagnosis. Seizures / etiology


59. Chen CL, Shen CC, Wang J, Lu CH, Lee HT: Central neurocytoma: a clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg; 2008 Feb;110(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Central neurocytoma is a rare intraventricular brain tumor that affects young adults and presents with increased intracranial pressure secondary to obstructive hydrocephalus.
  • In this report, we describe the diagnosis and treatment of central neurocytoma in a series of patients at our institution.
  • PATIENTS AND METHODS: Our series of nine patients (M:F=2:7, mean age, 28.2 years) with ventricular tumors showed typical radiological, histologic and immunohistochemical features of central neurocytoma.
  • Most patients received craniotomy with removal of the tumor through transcallosal or transcortical approach.
  • CONCLUSION: Although central neurocytoma is generally a benign neoplasm, some variant forms of recurrence are also present.
  • Recurrent tumors are often local and the patients seem to recover well after a second resection followed by radiotherapy.
  • Histologic features such as tumor proliferation (MIB-1 labeling index), vascular proliferation, and synaptophysin expression are often prominent in the recurrent tumor.
  • We recommend that these histologic features be considered for tumor recurrence during treatment and follow-up of these patients.

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1):7-12 [17639866.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] Surg Neurol. 2001 Feb;55(2):74-8 [11301084.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):879-82 [11702880.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1365-7 [12015858.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):126-32 [12046730.001]
  • [Cites] Neurology. 2002 Oct 22;59(8):1268-70 [12391364.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):256-60 [12541233.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):255-9 [12675319.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):560-5 [14670681.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Acta Neuropathol. 1990;79(5):473-9 [2109481.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):231-8 [2086738.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):585-91 [1901927.001]
  • [Cites] Neuroradiology. 1991;33(2):143-8 [2046899.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):32-7 [1727166.001]
  • [Cites] Radiology. 1992 Mar;182(3):787-92 [1535895.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1350-5 [8339224.001]
  • [Cites] Acta Radiol. 1993 Sep;34(5):520-6 [8369193.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] Surg Neurol. 1994 Oct;42(4):335-9 [7974132.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Aug;97(3):219-28 [7586853.001]
  • [Cites] Surg Neurol. 1996 Jan;45(1):49-56 [9190699.001]
  • [Cites] J Neurosurg. 1996 May;84(5):742-7 [8622146.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):790-5 [9024717.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Cancer. 1997 May 15;79(10):1995-2002 [9149028.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):279-83 [9258819.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):155-9 [10393370.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):506-9 [10470830.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):53-9 [15719276.001]
  • [Cites] Neurosurg Rev. 2005 Apr;28(2):96-103 [15580370.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):683-8 [16163043.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):415-8 [16826361.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):286-92; discussion 292 [16604374.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):270-85; discussion 285 [16941163.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54 [17187939.001]
  • [Cites] Neuroradiology. 2007 Jul;49(7):551-4 [17364196.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • (PMID = 18022760.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS039918-03; United States / NINDS NIH HHS / NS / R01 NS039918-02; United States / NINDS NIH HHS / NS / NS039918-02; United States / NINDS NIH HHS / NS / R01 NS039918-01; United States / NINDS NIH HHS / NS / NS039918-03; United States / NINDS NIH HHS / NS / NS039918-01
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS39918; NLM/ PMC2702989
  •  go-up   go-down


60. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


61. Uro-Coste E, Ssi-Yan-Kai G, Guilbeau-Frugier C, Boetto S, Bertozzi AI, Sevely A, Lolmede K, Delisle MB: Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation. J Neurooncol; 2010 May;98(1):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation.
  • Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are rare intracranial tumors that mostly occur in the first 2 years of life and involve superficial cerebral cortex.
  • Magnetic resonance imaging showed a temporal tumor with prepontine and interpeduncular extension, and two other distinct localizations in cisterna magna and left cerebellar hemisphere.
  • When the tumor is large, multilobular involvement is common, but multiple location of DIG is, on the contrary, very rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Brain / diagnostic imaging. Brain / pathology. Child, Preschool. Humans. Magnetic Resonance Imaging / methods. Male. Radiography. Tomography Scanners, X-Ray Computed


62. Lázaro BC, Landeiro JA: Tectal plate tumors. Arq Neuropsiquiatr; 2006 Jun;64(2B):432-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tectal plate tumors.
  • Tectal plate is a rare location for a tumor.
  • Many papers have described different types of pathology arising in that location including tumors, vascular lesions, inflammatory and infectious processes.
  • Open surgery was performed in three cases (due to tumor enlargement or need for the exact diagnosis).
  • In our series, except in the metastatic tumor case and the cavernoma, the other types of lesion consisted of low grade gliomas.
  • These lesions represent a different type of brain stem tumor sharing a common good prognosis, with a benign behavior.
  • We believe that tectal tumors must be managed case by case.
  • When a patient presents with a benign lesions in the tectal region, treating the main symptom--hydrocephalus--should be the first attempt in management of these lesions.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Tectum Mesencephali

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917614.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


63. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


64. Tuniz F, Soltys SG, Choi CY, Chang SD, Gibbs IC, Fischbein NJ, Adler JR Jr: Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery; 2009 Nov;65(5):898-907; discussion 907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study.
  • OBJECTIVE: Although radiosurgery plays an important role in managing benign cranial base lesions, the potential for increased toxicity with single-session treatment of large tumors is a concern.
  • In this retrospective study, we report the intermediate-term rate of local control, morbidity, and clinical outcomes of patients with large cranial base tumors treated with multisession stereotactic radiosurgery with the CyberKnife (Accuray, Inc., Sunnyvale, CA).
  • METHODS: Between 1999 and 2008, 34 consecutive patients with large (>15 cm), benign cranial base tumors (21 meningiomas, 9 schwannomas, 4 glomus jugulare tumors) underwent primary or postoperative radiosurgical treatment using a multisession approach at Stanford University and were considered in this retrospective study.
  • CyberKnife radiosurgery was delivered in 2 to 5 sessions (median, 3 sessions) to a median tumor volume of 19.3 cm (range, 15.8-69.3 cm).
  • To date, all tumors remain locally controlled.
  • CONCLUSION: Over our modest length of follow-up, multisession radiosurgery appears to be a safe and effective option for selected large, benign brain and cranial base lesions.
  • [MeSH-major] Radiosurgery / methods. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834402.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res; 2005 Aug 1;65(15):6726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
  • Malignant gliomas are deadly brain tumors characterized by diffuse invasion into the surrounding brain tissue.
  • Here we describe for the first time the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms, B/b(sia) and B/b(Deltag), which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies.
  • In addition, its absence from benign gliomas prompts its use as a diagnostic marker to distinguish primary brain tumors of similar histology but different pathologic course.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioma / metabolism. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01/NS35228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Brevican; 0 / Carrier Proteins; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


66. Nagesh V, Tsien CI, Chenevert TL, Ross BD, Lawrence TS, Junick L, Cao Y: Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1002-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study.
  • PURPOSE: To quantify the radiation-induced changes in normal-appearing white matter before, during, and after radiotherapy (RT) in cerebral tumor patients.
  • METHODS AND MATERIALS: Twenty-five patients with low-grade glioma, high-grade glioma, or benign tumor treated with RT were studied using diffusion tensor magnetic resonance imaging.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Aug;236(2):647-52 [16040920.001]
  • [Cites] J Head Trauma Rehabil. 2003 Jul-Aug;18(4):307-16 [16222127.001]
  • [Cites] Magn Reson Med. 2006 Feb;55(2):302-8 [16408263.001]
  • [Cites] J Neurosci Res. 2006 Feb 15;83(3):392-402 [16397901.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):884-90 [16484697.001]
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] Eur J Neurol. 2007 May;14(5):540-7 [17437614.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 [17306935.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):51-5 [10656372.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):101-11 [10780628.001]
  • [Cites] Radiat Res. 2000 Apr;153(4):357-70 [10798963.001]
  • [Cites] Magn Reson Med. 2000 Aug;44(2):259-68 [10918325.001]
  • [Cites] J Med Primatol. 2001 Apr;30(2):81-7 [11491408.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Oct;82(10):1461-71 [11588754.001]
  • [Cites] Radiology. 2001 Nov;221(2):349-58 [11687675.001]
  • [Cites] Radiother Oncol. 2002 Apr;63(1):107-20 [12065111.001]
  • [Cites] Neuroimage. 2002 Nov;17(3):1429-36 [12414282.001]
  • [Cites] Neuroimage. 2003 Nov;20(3):1714-22 [14642481.001]
  • [Cites] Acta Neuropathol. 1968 Nov 1;11(4):267-74 [5710040.001]
  • [Cites] Cancer. 1979 Oct;44(4):1256-72 [387205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1966-72 [6478431.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):635-40 [3731021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):319-30 [2841263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1371-81 [2461919.001]
  • [Cites] Br J Radiol. 1988 Nov;61(731):1043-52 [3208008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):37-42 [2298633.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):689-96 [2004945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):1089-91; discussion 1093-4 [1639645.001]
  • [Cites] Radiother Oncol. 1993 Oct;29(1):60-8 [8295989.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2828-35 [7954244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Brain Res. 1995 Feb 6;671(1):141-8 [7728526.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan;12(1):45-62 [7502957.001]
  • [Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]
  • [Cites] Magn Reson Med. 1996 Dec;36(6):893-906 [8946355.001]
  • [Cites] Magn Reson Med. 1998 Jun;39(6):928-34 [9621916.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):480-4 [10201420.001]
  • [Cites] Brookhaven Symp Biol. 1961 Nov;14:176-99 [14010110.001]
  • [Cites] J Neurol Sci. 2005 Mar 15;229-230:195-200 [15760639.001]
  • [Cites] Neuroimage. 2005 May 15;26(1):132-40 [15862213.001]
  • (PMID = 18313524.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113699-02; United States / NCI NIH HHS / CA / R21 CA113699; United States / NCI NIH HHS / CA / R21 CA113699-02; United States / NCI NIH HHS / CA / P01 CA059827; United States / NCI NIH HHS / CA / 3P01 CA59827; United States / NCI NIH HHS / CA / CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878-01A2; United States / NCI NIH HHS / CA / P02 CA85878; United States / NCI NIH HHS / CA / P01 CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / R21 CA11369901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS42273; NLM/ PMC2376211
  •  go-up   go-down


67. Samaila MO, Mbibu HN, Oluwole OP: Human mycetoma. Surg Infect (Larchmt); 2007 Oct;8(5):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the disease may present without these characteristic features, thus causing diagnostic difficulty with other chronic granulomatous infections such as tuberculosis or benign skin lesions.
  • The range of clinical misdiagnoses included skin tuberculosis, fibroma, amelanotic melanoma, basal-cell carcinoma, and brain tumor.
  • Knowledge of mycetoma pathology is important for prompt diagnosis and treatment of this indolent clinical entity.
  • [MeSH-major] Mycetoma / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycetoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999585.001).
  • [ISSN] 1096-2964
  • [Journal-full-title] Surgical infections
  • [ISO-abbreviation] Surg Infect (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Han X, Dong Y, Sun K, Lu Y: A huge occipital osteoblastoma accompanied with aneurysmal bone cyst in the posterior cranial fossa. Clin Neurol Neurosurg; 2008 Mar;110(3):282-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoblastoma is an infrequent benign tumor and skull involvement is extremely rare.
  • MRI scan and CT three-dimensional reconstruction revealed that the tumor (approximately 8.5 cm x 6 cm x 5 cm) occupied nearly half volume of the posterior cranial fossa.
  • The cerebellum, the forth ventricle and brain stem were compressed remarkably and hydrocephalus was noted.
  • The tumor mass was multiloculated cystic and highly vascular.
  • Pathological examination revealed that the lesion was a benign osteoblastoma with secondary aneurysmal bone cyst (ABC).
  • Despite the benign nature of osteoblastoma, local recurrence after incomplete resection is not rare and malignant transformation during recurrence may occur even after adequate surgery.
  • [MeSH-major] Bone Cysts, Aneurysmal / pathology. Brain Neoplasms / pathology. Occipital Lobe. Osteoblastoma / pathology
  • [MeSH-minor] Aged. Brain / pathology. Cranial Fossa, Anterior / pathology. Cranial Fossa, Anterior / surgery. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Osteoblasts / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055104.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


69. Albers AC, Gutmann DH: Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother; 2009 Apr;9(4):535-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is an inherited autosomal dominant disorder characterized by numerous cutaneous features, including café-au-lait macules, skinfold freckling and iris hamartomas.
  • In addition, individuals with NF1 are prone to the development of both benign and malignant tumors.
  • The most common CNS tumor in children and adults with NF1 is the glioma.
  • Regular ophthalmologic evaluations in children are essential for the effective management of these tumors in patients with NF1.
  • [MeSH-major] Brain Neoplasms / complications. Glioma / complications. Neurofibromatosis 1 / complications


70. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • The diagnosis of an oncocytic adrenal cortical adenoma was made.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenocortical Adenoma / pathology. Spinal Cord Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Liu AL, Wang C, Sun S, Wang M, Liu P: Gamma knife radiosurgery for tumors involving the cavernous sinus. Stereotact Funct Neurosurg; 2005;83(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for tumors involving the cavernous sinus.
  • OBJECTIVE: To study the features of diagnosis and radiosurgery of tumors involving the cavernous sinus.
  • Our experience of treating cavernous sinus tumors by GK was analyzed retrospectively.
  • RESULTS: A Hundred and forty-four (82.3%) patients were followed from 1 to 84 months (median 32.5 months); total tumor control rate was 94%.
  • Surgery was performed after radiosurgery in 3 patients because of tumor enlargement.
  • Metastatic tumor in the cavernous sinus was highly sensitive to irradiation.
  • CONCLUSION: With high tumor control rate and few complications, GK surgery could become a main option for small benign or residual tumors involving the cavernous sinus.
  • It is also very useful as part of comprehensive therapy for metastatic tumors in the cavernous sinus.
  • [MeSH-major] Brain Neoplasms / surgery. Cavernous Sinus / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma / surgery. Radiosurgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adolescent. Adult. Aged. Child. Chordoma / pathology. Chordoma / surgery. Female. Follow-Up Studies. Hemangioma, Cavernous / pathology. Hemangioma, Cavernous / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860936.001).
  • [ISSN] 1011-6125
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


72. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


73. Kumar R, McClain D, Young R, Carlson GA: Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells. J Gen Virol; 2008 Jun;89(Pt 6):1525-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prion replication by conversion of benign PrPC isoforms into disease-specific PrPSc isoforms is intimately involved in prion disease pathogenesis and may be initiated in cholesterol-rich caveolae-like domains (CLD).
  • Elevation of ABCA1 in prion-infected brain is not a direct consequence of local PrPSc accumulation, indeed levels of ABCA1 are comparable in brain regions that differ dramatically in the amount of PrPSc.
  • [MeSH-minor] ATP Binding Cassette Transporter 1. Animals. Brain / metabolism. Cell Line, Tumor. Cholesterol / metabolism. Immunoblotting. Mice. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Feb;24(2):192-6 [10655069.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28634-40 [10893411.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15137-45 [11328826.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3158-66 [11073951.001]
  • [Cites] Nature. 2001 Aug 16;412(6848):739-43 [11507642.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5675-82 [11739375.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25457-64 [11994310.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48508-13 [12384498.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13244-56 [12547833.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14983-90 [14754889.001]
  • [Cites] Mol Biol Cell. 2004 Sep;15(9):4031-42 [15229281.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):556-64 [15369787.001]
  • [Cites] J Virol. 2004 Oct;78(20):11051-60 [15452225.001]
  • [Cites] Cell. 1990 Nov 16;63(4):673-86 [1977523.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):18217-23 [1680859.001]
  • [Cites] Nature. 1992 Apr 16;356(6370):577-82 [1373228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5690-4 [7911243.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):121-32 [7698979.001]
  • [Cites] Mol Med. 1994 Nov;1(1):19-30 [8790598.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14945-9 [8962161.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2333-8 [9122195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83 [9811807.001]
  • [Cites] Clin Microbiol Rev. 1999 Jul;12(3):429-44 [10398674.001]
  • [Cites] Mol Med. 1999 Jun;5(6):406-18 [10415165.001]
  • [Cites] J Clin Invest. 1999 Oct;104(8):R25-31 [10525055.001]
  • [Cites] Trends Cell Biol. 2005 Feb;15(2):102-11 [15695097.001]
  • [Cites] Mol Cell Neurosci. 2006 Feb;31(2):346-53 [16278084.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):527-33 [16373613.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 22;348(2):697-702 [16890918.001]
  • [Cites] J Neurochem. 2007 Aug;102(3):834-47 [17437544.001]
  • (PMID = 18474570.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS041997; United States / NINDS NIH HHS / NS / P01 NS041997-070001; United States / NINDS NIH HHS / NS / NS41997
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATP Binding Cassette Transporter 1; 0 / ATP-Binding Cassette Transporters; 0 / PrPC Proteins; 0 / PrPSc Proteins; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ NIHMS115814; NLM/ PMC2706533
  •  go-up   go-down


74. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.
  • Ionizing radiation is an established risk factor for brain tumors, yet quantitative information on the long-term risk of different types of brain tumors is sparse.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • The mean estimated radiation dose to the brain was 1.5 Gy.
  • Survival analysis using Poisson regression was performed to estimate the excess relative and absolute risks (ERR, EAR) for brain tumors.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The risk of both types of tumors was positively associated with dose.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.
  • The ERR for both types of tumor remains elevated at 30-plus years after exposure.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / statistics & numerical data. Risk Assessment / methods. Tinea Capitis / epidemiology. Tinea Capitis / radiotherapy


75. Xian J, Xu X, Wang Z, Yang B, Li B, Man F, Chen Q, Shi J, Zhang Y: MR imaging findings of the uveal schwannoma. AJNR Am J Neuroradiol; 2009 Apr;30(4):769-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Uveal schwannoma is a rare benign neoplastic proliferation of pure Schwann cells.
  • MR imaging findings of the tumor were evaluated with emphasis on the location, size, shape, margin, signal intensity, and pattern of enhancement.
  • The tumors were hypointense to the vitreous body on fast SE (FSE) T2-weighted images (T2WI) in 4 patients and isointense in 1.
  • However, with respect to the brain, uveal schwannoma demonstrated isointensity on T1WI SE images in all 6 patients, isointensity on FSE T2WI images in 5 patients, and hyperintensity on T2WI SE images in 1.
  • CONCLUSIONS: Uveal schwannoma should be included in the differential diagnosis when an oval isointense mass relative to brain is seen in the ciliochoroidal region.
  • [MeSH-major] Choroid Neoplasms / pathology. Iris Neoplasms / pathology. Magnetic Resonance Imaging. Neurilemmoma / pathology. Uveal Neoplasms / pathology
  • [MeSH-minor] Adult. Choroid / pathology. Ciliary Body / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies. Schwann Cells / pathology. Uvea / pathology. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164439.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Zhao YC, Li NY, Zhou XJ, Zhou HB, Ma HH, Zhang RS: [Clinicopathologic study of pilocytic astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Sep;37(9):609-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic degeneration was noted in 41 cases (60.3%), and enhancement of the tumor was noted in 43 cases (87.8%).
  • Total tumor excision was performed in 35 patients, subtotal tumor excision was performed in 31 patients, and the procedures of other 2 patients were not clear.
  • Among 51 patients with follow-up information, 44 were alive, 7 had recurrent tumor, and 7 died.
  • Tumors with classic histopathology demonstrated biphasic pattern of growth, consisting of compact elongated bipolar astrocytes associated with rosenthal fibers, and less cellular areas of multipolar cells with granular bodies and microcyst.
  • All cases showed diffuse positive staining for GFAP and low expression for Ki-67, except 1 anaplastic tumor with 10% Ki-67 indices.
  • Tumors with subarachnoid space involvement showed positive reticular fiber staining and negative EMA staining.
  • CONCLUSIONS: PA is a benign, WHO grade I tumor with favorable prognosis, and does not require radiotherapy after total resection.
  • The tumor can be mistaken as higher-grade astrocytoma when involving the subarachnoid space, and with cytological atypia, leading to unnecessary radiotherapy after surgery.
  • The outcome for patients with brainstem tumor or anaplastic PA is poor.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glial Fibrillary Acidic Protein / genetics. Recurrence

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094585.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


77. Gheri CF, Buccoliero AM, Pansini G, Castiglione F, Garbini F, Moncini D, Maccari C, Mennonna P, Pellicanò G, Ammannati F, Taddei GL: Lipoastrocytoma: Case report and review of the literature. Neuropathology; 2010 Oct;30(5):553-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoastrocytoma is an extremely rare tumor, with only six cases described.
  • Subtotal excision of the tumor was accomplished.
  • Histologically the tumor showed the classical histology of low-grade astrocytoma and a portion of the lesion was composed of lipid-laden cells.
  • Our case has a benign postoperative behavior, also after subtotal excision, with restrictions due to the short follow-up.
  • It is important to record each new case of this rare tumor to produce a better characterization of this lesion.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Lipomatosis / pathology
  • [MeSH-minor] Adult. Brain Stem / pathology. Cerebellum / pathology. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Society of Neuropathology.
  • (PMID = 20113404.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; lipid vacuole / lipoastrocytoma / lipomatous / low grade astrocytoma
  •  go-up   go-down


78. Shingu T, Akiyama Y, Daisu M, Maruyama N, Matsumoto Y, Miyazaki T, Nagai H, Yamamoto Y, Yamasaki T, Yoshida M, Maruyama R, Moritake K: Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):222-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and T(2)*-weighted magnetic resonance imaging revealed hemorrhage in the tumor located in the right basal ganglia, thalamus, and hypothalamus.
  • Although neither symptomatic hemorrhage nor late benign recurrence is common, careful long-term follow up is necessary for patients with pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527050.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. Coope DJ, Cízek J, Eggers C, Vollmar S, Heiss WD, Herholz K: Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med; 2007 Dec;48(12):1971-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map.
  • (11)C-Methionine PET is a well-established technique for evaluating tumor extent for diagnosis and treatment planning in neurooncology.
  • Image interpretation is typically performed using the ratio of uptake within the tumor to a reference region.
  • Selection of a reference region can be highly user dependant, and identifying a representative normal region may be complicated by midline or multifocal tumors.
  • We hypothesized that current coregistration methods would enable interpretation of methionine PET images with reference to an averaged normal uptake map, allowing better standardization of scan analysis and increasing the sensitivity to tumor infiltration, particularly of white matter regions.
  • METHODS: A normal methionine uptake map was prepared from the normal hemispheres of 20 scans performed on patients with benign or low-grade lesions.
  • A standardized method for applying the normal uptake map in brain tumors was developed and evaluated in a sample of 18 scans (6 grade II, 6 grade III, and 6 grade IV gliomas).
  • Tumor extent was compared with that derived from a mirrored contralateral reference region method.
  • Correlation coefficients were calculated between the uptake ratios for tumor to normal uptake map versus tumor to mirrored reference region.
  • Uptake ratios within the tumor varied slightly with the normalization methods used but correlated closely with the ratio to a single reference value.
  • The tumor uptake ratios obtained correlated closely with a standard reference value technique, whereas the described method allowed for better standardization of the image analysis.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Image Processing, Computer-Assisted / standards. Methionine / pharmacokinetics. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006617.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


80. Jozwiak J, Kotulska K, Grajkowska W, Jozwiak S, Zalewski W, Oldak M, Lojek M, Rainko K, Maksym R, Lazarczyk M, Skopinski P, Wlodarski P: Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev; 2007 Jun;29(5):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TS), autosomal dominant disorder manifested by the formation of usually benign tumors in the brain, heart, kidneys and skin, results from an inactivating mutation in one of two tumor suppressor genes TSC1 or TSC2.
  • In order to test this hypothesis we evaluated samples of four subependymal giant cell astrocytomas (SEGAs), brain tumors developing in the progress of TS.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / physiopathology. Brain Neoplasms / complications. Brain Neoplasms / physiopathology. Signal Transduction / physiology. Tuberous Sclerosis / etiology. Tuberous Sclerosis / physiopathology. Up-Regulation / physiology. Wnt Proteins / physiology


81. Park JE, Park MC, Yoon SH, Kim JH: Intradural extracerebral choristoma. Case report and review of the literature. Pediatr Neurosurg; 2008;44(4):318-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain magnetic resonance imaging demonstrated a 2.0-cm-sized, round-shaped mass in the frontal midline.
  • RESULTS: Surgical exploration revealed a yellowish tumor mass with whitish soft tissue material within the tumor, adherence to the surrounding blood vessels, and therefore subtotal removal was performed.
  • Follow-up at 18 months later showed that there was no evidence of tumor regrowth or neurological deficit, and the neurological development was normal.
  • CONCLUSION: The authors described a rare case of intracranial extracerebral neuroglial choristoma accompanied by both nasopharyngeal teratoma and cleft palate and suggested its benign nature from the low MIB-1 labeling index.
  • [MeSH-major] Brain Diseases / diagnosis. Choristoma / diagnosis. Neuroglia
  • [MeSH-minor] Cleft Palate / complications. Female. Humans. Infant. Nasopharyngeal Neoplasms / complications. Teratoma / complications

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18504419.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 18
  •  go-up   go-down


82. Gallina P, Buccoliero AM, Mariotti F, Mennonna P, Di Lorenzo N: Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course. J Neurosurg; 2006 Nov;105(5):736-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course.
  • OBJECT: Oncocytic meningioma has recently been recognized as a distinct morphological variant of intracranial meningothelial neoplasms, and only a few cases have been reported in the literature.
  • The first description of this lesion, which was based on data in six cases, revealed a potentially aggressive nature with a tendency to infiltrate the brain and to recur.
  • Histologically, the tumors were composed of sheets, nests, and cords of large polygonal neoplastic cells with finely granular cytoplasm.
  • Mitosis was also absent or exceedingly rare, and no brain cortex infiltration was observed.
  • At the last follow-up evaluation, all patients were asymptomatic and magnetic resonance imaging examinations demonstrated no evidence of tumor recurrence.
  • In fact, the histological features as well as the long-term favorable clinical course may suggest benign behavior of such neoplasms, as in the common forms of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Oxyphil Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121136.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


83. Maiuri F, Donzelli R, Mariniello G, Del Basso De Caro ML, Colella A, Peca C, Vergara P, Pettinato G: Local versus diffuse recurrences of meningiomas: factors correlated to the extent of the recurrence. Clin Neuropathol; 2008 Jan-Feb;27(1):29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: 55 patients with benign (WHO I) meningiomas which recurred after seemingly complete removal were reviewed; 40 (Group I) had local or peripheral recurrences (< 3 cm from the initial dural attachment) and 15 (Group II) had distant and diffuse recurrences.
  • Patient age and sex, tumor location, interval of recurrence, tumor shape, type of brain-tumor interface, histological subtype, mitotic index (MI) and progesterone receptor (PR) expression of the initial tumor, histological WHO Grade of the recurrent tumor and patient outcome were analyzed and correlated with the pattern of recurrence.
  • RESULTS: Flat-shaped meningiomas with large dural attachment showed a significantly higher rate of diffuse recurrences than round tumors, whereas the brain-tumor interface and the tumor location were not relevant (excepting the lack of convexity meningiomas in the group of diffuse tumors).
  • There were no significant differences of histology, MI and PR expression of the initial tumor and histological grade of the recurrent tumor between the two groups.
  • CONCLUSIONS: The different patterns of meningioma recurrences (local, peripheral, diffuse) are not correlated with the tumor location and histology and do not represent a different biological tumor progression.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18257472.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci; 2006 Dec;256(8):516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To assess the long-term survival of brain tumor patients, and in particular to evaluate the relation of quality of life (QOL) to survival among low-grade glioma patients.
  • METHODS: The postoperative survival of 101 brain tumor patients was followed from surgery (1990-1992) until the end of the year 2003.
  • RESULTS: The mean survival times in years (SD) were significantly related to tumor malignancy, being the shortest, 1.9 (0.6), for patients with high-grade gliomas, while patients with low-grade gliomas or a benign brain tumor had mean survival times of 9.1 (1.0) and 11.6 (0.5), respectively.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / psychology. Depressive Disorder / mortality. Depressive Disorder / psychology. Glioma / mortality. Glioma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Aged. Disease Progression. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / mortality. Postoperative Complications / psychology. Prognosis. Statistics as Topic. Survival Analysis


85. Alkan O, Yildirim T, Kizilkiliç O, Tan M, Cekinmez M: A case of ecchordosis physaliphora presenting with an intratumoral hemorrhage. Turk Neurosurg; 2009 Jul;19(3):293-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ecchordosis physaliphora is a rare congenital, benign, hamartomatous, retroclival mass derived from notochordal tissue that is typically located intradurally in the prepontine cistern.
  • In rare cases, ecchordosis physaliphora can be symptomatic due to tumor expansion and compression of the surrounding structures and extratumoral hemorrhage.
  • [MeSH-major] Brain Diseases / etiology. Hamartoma / complications. Notochord / pathology. Subarachnoid Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621298.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


86. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS: Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery; 2007 Apr;60(4):750-9; discussion 759-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The lack of meningioma models has hindered research on the pathogenesis and treatment of this commonly diagnosed primary brain tumor.
  • Animal models of meningioma have been difficult to develop, especially those derived from Grade I tumors, which display very slow growth rates, senesce at early passages, and infrequently survive as explants in vivo.
  • In this study, the authors report the establishment of two benign immortalized meningioma cell lines, Me10T and Me3TSC, that can serve as useful models of human meningioma.
  • In addition, immortalized cell lines were implanted subdurally into mice to confirm their ability to form tumors.
  • RESULTS: Two immortalized benign meningioma cell lines, Me10T and Me3TSC, transduced with catalytic subunit human telomerase reverse transcriptase alone or human telomerase reverse transcriptase and SV40 large T antigen, were established.
  • After subdural injection into athymic nude mice, both cell lines formed identifiable tumors with histological features and immunostaining patterns of human meningioma.
  • [MeSH-major] Cell Line, Tumor / enzymology. Cell Line, Tumor / pathology. Cell Transformation, Neoplastic / genetics. Meningioma / enzymology. Meningioma / genetics. Telomerase / genetics. Transfection / methods

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415213.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


87. Xu Y, Jing Y, Ma S, Ma F, Wang Y, Ma W, Li Q: Primary angioleiomyoma in the sellar region: a case report and literature review. Clin Neuropathol; 2010 Jan-Feb;29(1):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Angioleiomyoma (vascular leiomyomas, angiomyoma) is a rare, benign soft tissue tumor which consists of a mixture of well-differentiated smooth muscle cells and thick-walled vessels.
  • Gross total resection of the tumor was then performed.
  • The pertinent literature regarding the features of this tumor was reviewed and discussed.
  • CONCLUSIONS: Intracranial angioleiomyoma is a benign soft tissue tumor with excellent prognosis.
  • Early diagnosis of this tumor is difficult.
  • [MeSH-major] Angiomyoma / pathology. Brain / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adrenocorticotropic Hormone / metabolism. Early Diagnosis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040329.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 14
  •  go-up   go-down


88. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A: Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol; 2007 Oct;9(4):447-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for the use of radiotherapy in the management of a variety of benign intracranial neoplastic and nonneoplastic pathologies are increasing.
  • Although the short-term risks are minimal, the long-term risks of radiation-induced de novo secondary neoplasms or malignant progression of the primary benign tumor need to be considered.
  • There are currently 19 reported cases of tumors linked with stereotactic radiotherapy/radiosurgery, to which we add our second institutional experience of a patient who succumbed to a glioblastoma multiforme (GBM) after stereotactic radiotherapy for an acoustic neuroma (AN).
  • Review of these 20 cases revealed 10 de novo secondary tumors, of which eight were malignant, with six being malignant gliomas.
  • Accelerated growth of the primary benign AN, some 2 to 6 years after focused radiotherapy, was found in six of eight NF2 patients, with pathological verification of a malignant nerve sheath tumor documented in most.
  • [MeSH-major] Brain Neoplasms / etiology. Glioblastoma / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroma, Acoustic / surgery. Radiosurgery / adverse effects


89. Carlson ML, Babovic-Vuksanovic D, Messiaen L, Scheithauer BW, Neff BA, Link MJ: Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg; 2010 Jan;112(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas.
  • The gene responsible for the development of NF2 acts as a tumor suppressor gene.
  • Stereotactic radiotherapy (SRT) or single-fraction stereotactic radiosurgery has been increasingly used in the past decades to treat benign tumors in patients with NF2.
  • These radiotherapy methods are less invasive and can be potentially used to treat multiple tumors in a single session.
  • Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2.
  • Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
  • [MeSH-major] Brain Stem Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neurofibromatosis 2 / surgery. Radiosurgery / adverse effects. Rhabdomyosarcoma / etiology
  • [MeSH-minor] Adult. Brain Neoplasms / etiology. Brain Neoplasms / surgery. Brain Stem / pathology. Brain Stem / radiation effects. Brain Stem / surgery. Ear Neoplasms / etiology. Ear Neoplasms / surgery. Fatal Outcome. Female. Humans. Neurilemmoma / etiology. Neurilemmoma / surgery. Vestibular Diseases / etiology. Vestibular Diseases / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):209. Scheithauer, Bernd B [corrected to Scheithauer, Bernd W]
  • (PMID = 19575577.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Pascual Castroviejo I, Pascual Pascual S, Velázquez Fragua R, Viaño J, Garcia Segura JM: [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients]. Neurologia; 2007 Dec;22(10):846-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients].
  • [Transliterated title] Tumores de tronco cerebral asociados con neurofibromatosis tipo 1. Presentación de 20 pacientes infantiles.
  • OBJECTIVE: To describe the clinical and imaging findings of 20 patients (12 women and 8 men) with brain stem tumors associated with neurofibromatosis type 1 (NF1).
  • Thirteen of the 20 patients (65 %) also had optic pathway tumor.
  • Brain stem tumor identification occurred at the same time as NF1 in the patients who were studied by MR at the time of the first consult.
  • RESULTS: Brain stem identification occurred at the same time as that of the NF1 in patients who were studied by MR from the beginning.
  • Diffuse or localized medullary enlargement was the most frequent MR imaging and appeared in 13 patients (65%), followed by the tumor that involved all brain stem (pontine and medullary areas) that appeared in 6 patients (30 %).
  • In the last group, one tumor showed extension through brain stem and medial cerebellar parts, another was located in the aqueduct and in the periaqueductal areas and showed slow progressive growth, and one third patient had a tumor with aggressive signs in the SMR study.
  • Another patient had an aggressive tumor that involved the left optic nerve, chiasm, mesencephalon and upper right pontine areas.
  • The histological study of the tumoral biopsic tissue of the two last patients showed astrocitoma degree 1 (benign tumor).
  • The two aggressive tumors were treated with radiotheraphy and chemotherapy and they are still alive 4 and 7 years respectively after treatment.
  • Only one of the 20 patients died, although it was due to a malignant chiasmatic tumor, that had been treated twenty years before, and not by the brain stem tumor.
  • CONCLUSIONS: In NF1, brain stem tumors are the most frequent tumors of the posterior fossa and the second most frequent of the central nervous system (CNS).
  • MR and SMR are necessary to a correct identification of the tumor in some patients.
  • Most of these tumors are benign.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Brain Stem. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neurofibromatosis 1 / complications


91. Waltereit R, Welzl H, Dichgans J, Lipp HP, Schmidt WJ, Weller M: Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J Neurochem; 2006 Jan;96(2):407-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TSC starts in early childhood and is characterized by cerebral hamartomas (benign tumours), severe epilepsy and cognitive deficits such as mental retardation and autism.
  • The hamartomas are characterized by loss of the remaining wild-type TSC allele, and clinical data implicate cerebral hamartomas in the generation of epileptic seizures, which may play a significant role in the development of mental retardation.
  • We therefore hypothesized that the heterozygous mutation itself, besides cerebral hamartomas, contributes to the pathogenesis of cognitive deficits and possibly also epilepsy.
  • Here, we show that young adult TSC2+/- rats, which are virtually free of cerebral hamartomas, exhibit enhanced episodic-like memory and enhanced responses to chemically-induced kindling.
  • [MeSH-major] Epilepsy / etiology. Kindling, Neurologic. Memory, Short-Term. Mutation. Tuberous Sclerosis / genetics. Tuberous Sclerosis / psychology. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epilepsy Curr. 2006 Nov-Dec;6(6):210-2 [17260062.001]
  • (PMID = 16300636.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1
  •  go-up   go-down


92. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Myxopapillary ependymomas (MPEs) have historically been thought to be benign tumors occurring most frequently in adults.
  • Only 8 to 20% of these tumors occur in the first two decades of life, making this tumor a rarity in pediatric neurosurgery.
  • In those cases in which patients underwent screening for CNS tumor dissemination, however, the incidence of disseminated disease was 58% (seven of 12 patients).
  • In pediatric patients MPEs may spread throughout the CNS via cerebrospinal fluid pathways; therefore, MR imaging of the entire CNS axis is recommended at both presentation and follow-up review to detect tumor dissemination.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology


93. Fukaya R, Yoshida K, Ohira T, Kawase T: Trigeminal schwannomas: experience with 57 cases and a review of the literature. Neurosurg Rev; 2010 Apr;34(2):159-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trigeminal schwannoma is a mostly benign tumor that can be cured by complete resection.
  • Over the last few decades, several pioneers have developed surgical approaches enabling the total removal of such tumors.
  • Since 1990, all such patients have been treated using three main types of middle fossa skull base approaches, which minimize the exposure of the brain: the anterior transpetrosal approach, subtemporal interdural approach (Dolenc), or a combination of these approaches.
  • Before 1990, total tumor removal was achieved in only three of eight patients (38%).
  • After 1990, the tumors were totally removed in 43 patients (90%) and were nearly completely removed in an additional three patients (6%).
  • However, total surgical removal after surgery and Gamma knife surgery was very difficult because of dense adhesions to the brain stem and cranial nerves.
  • A correct anatomical knowledge is critical for minimizing brain exposure and avoiding surgical complications.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Neurilemmoma / surgery. Trigeminal Nerve Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cranial Fossa, Middle / surgery. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Radiosurgery. Retrospective Studies. Skull Base / surgery. Temporal Bone / surgery. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1986;82(3-4):118-22 [3491493.001]
  • [Cites] Acta Neurochir (Wien). 1994;130(1-4):55-65 [7725943.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(9):1027-35 [8911538.001]
  • [Cites] J Neurosurg. 1995 May;82(5):719-25 [7714595.001]
  • [Cites] Chin Med J (Engl). 2005 Mar 5;118(5):436-40 [15780219.001]
  • [Cites] Surg Neurol. 2007 Dec;68(6):594-602 [18053854.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):850-60 [3057125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Neurosurg Focus. 2008;25(6):E6; discussion E6 [19035703.001]
  • [Cites] J Neurosurg. 2007 May;106(5):839-45 [17542528.001]
  • [Cites] Neurosurgery. 2003 Apr;52(4):783-90; discussion 790 [12657173.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):18-23 [17236483.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):506-11 [2795170.001]
  • [Cites] Neurol Med Chir (Tokyo). 2005 Oct;45(10):526-9 [16247239.001]
  • [Cites] Clin Neurosurg. 1953;1:11-54 [14379464.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4 Suppl 2):ONS270-7; discussion ONS277-8 [17041497.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):752-7 [17937219.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(7):711-9 [10481782.001]
  • [Cites] Neurosurg Rev. 2007 Oct;30(4):329-37; discussion 337 [17676346.001]
  • [Cites] Acta Neurochir (Wien). 1994;129(3-4):113-20 [7847150.001]
  • [Cites] Surg Neurol. 2004 Nov;62(5):435-44; discussion 444-6 [15518853.001]
  • [Cites] Am J Otolaryngol. 1984 Sep-Oct;5(5):301-33 [6437262.001]
  • [Cites] J Neurosurg. 1989 May;70(5):737-45 [2709114.001]
  • [Cites] Surg Neurol. 1988 Dec;30(6):452-6 [3222724.001]
  • [Cites] Pediatr Neurosci. 1987;13(4):198-201 [3331430.001]
  • [Cites] J Neurosurg Sci. 1995 Sep;39(3):165-70 [8965124.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):815-21; discussion 821-2 [14519213.001]
  • [Cites] J Neurosurg. 1999 Aug;91(2):202-11 [10433308.001]
  • [Cites] Br J Neurosurg. 1988;2(1):67-71 [3268164.001]
  • [Cites] Surg Neurol. 1975 Dec;4(6):497-503 [1188585.001]
  • [Cites] Surg Neurol. 1983 Apr;19(4):351-3 [6836494.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):233-40; discussion 240-1 [9482173.001]
  • [Cites] J Clin Neurosci. 2008 Jul;15(7):738-43 [18396403.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1002-7 [11958895.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):869-75; discussion 875-6 [2067611.001]
  • [Cites] J Neurosurg. 2009 Mar;110(3):553-8 [19301456.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):453-63 [11883829.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):727-32 [17937215.001]
  • [Cites] J Neurosurg. 1995 May;82(5):711-8 [7714594.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):527-34; discussion 534-6 [8875483.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):220-224 [28306474.001]
  • [Cites] Acta Neurochir (Wien). 2007 Nov;149(11):1133-7; discussion 1137 [17728994.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:89-102 [15707030.001]
  • (PMID = 20963463.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Bhatnagar AK, Gerszten PC, Ozhasaglu C, Vogel WJ, Kalnicki S, Welch WC, Burton SA: CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors. Technol Cancer Res Treat; 2005 Oct;4(5):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors.
  • Limited data exists for the use of radiosurgery for benign extracranial tumors.
  • The purpose of this study was to evaluate the feasibility, toxicity, and local control of patients with benign extracranial lesions treated with the CyberKnife Frameless Radiosurgery System.
  • From September 2001 thru January 2004, 59 benign tumors in 44 patients were treated using the CyberKnife a frameless image-guided radiosurgery system.
  • Of these tumors, there were 21 neurofibromas, ten schwannomas, eight meningiomas, eight hemangioblastomas, seven paragangliomas, two hemangiopericytomas, one pseudotumor, one ependymoma, and one arteriovenous malformation (AVM).
  • The anatomic locations of these tumors were spinal (25 cervical, four thoracic, 14 lumbar, and two sacral), neck (eight), orbital (three), brainstem (one), and foramen magnum (one).
  • The median tumor dose delivered was 16.0 Gy to the 80% isodose line (range 10-31 Gy).
  • The median tumor volume was 4.3 cc (range 0.14-98.6 cc).
  • This study suggests that CyberKnife Radiosurgery is a safe and efficacious treatment modality for benign tumors, even for those patients with recurrent previously irradiated lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Safety. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173828.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - ADGRG6 - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2004 Dec 15;78(6):796-802 [15523643.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):179-92 [15691760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8633-8 [15932943.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] BMC Bioinformatics. 2006;7:35 [16430768.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] BMC Bioinformatics. 2006;7:84 [16504070.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] Development. 2006 Aug;133(15):2875-86 [16790476.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D116-21 [17178752.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Development. 2007 Sep;134(18):3271-81 [17699610.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):105-16 [18242511.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):658-69 [19041782.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1359-64 [9973626.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):117-23 [10612798.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41229-36 [11514554.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Apr 15;28(8):755-63 [12698117.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2357-65 [15014110.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):645-53 [1696266.001]
  • [Cites] Glia. 1996 Aug;17(4):327-38 [8856329.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [CommentIn] EMBO Mol Med. 2009 Jul;1(4):198-200 [20049721.001]
  • (PMID = 20049725.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / K01-NS049191; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human
  • [Other-IDs] NLM/ PMC3378132
  •  go-up   go-down


96. Hourani R, Horská A, Albayram S, Brant LJ, Melhem E, Cohen KJ, Burger PC, Weingart JD, Carson B, Wharam MD, Barker PB: Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging; 2006 Feb;23(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children.
  • PURPOSE: To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and low-grade tumors in children.
  • MATERIALS AND METHODS: Thirty-two children (20 males and 12 females, mean age = 10 +/- 5 years) with primary brain lesions were evaluated retrospectively.
  • Nineteen patients had a neuropathologically confirmed brain tumor, and 13 patients had a benign lesion.
  • RESULTS: Considering all possible combinations of metabolite ratios, the best discriminant function to differentiate between nonneoplastic lesions and brain tumors was found to include only the ratio of Cho/Cr (Wilks' lambda, P = 0.012; 78.1% of original grouped cases correctly classified).
  • The best discriminant function to differentiate between high- and low-grade tumors included the ratios of NAA/Cr and Cho(norm) (Wilks' lambda, P = 0.001; 89.5% of original grouped cases correctly classified).
  • Cr levels in low-grade tumors were slightly lower than or comparable to control regions and ranged from 53% to 165% of the control values in high-grade tumors.
  • CONCLUSION: Proton MRSI may have a promising role in differentiating pediatric brain lesions, and an important diagnostic value, particularly for inoperable or inaccessible lesions.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Germinoma / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 Wiley-Liss, Inc.
  • (PMID = 16374884.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS042851; United States / NCRR NIH HHS / RR / P41RR15241
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


97. Szabó PM, Wiener Z, Tömböl Z, Kovács A, Pócza P, Horányi J, Kulka J, Riesz P, Tóth M, Patócs A, Gaillard RC, Falus A, Rácz K, Igaz P: Differences in the expression of histamine-related genes and proteins in normal human adrenal cortex and adrenocortical tumors. Virchows Arch; 2009 Aug;455(2):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the expression of histamine-related genes and proteins in normal human adrenal cortex and adrenocortical tumors.
  • Histamine is involved in the pathogenesis of several tumors; however, there are no data on its possible involvement in human adrenocortical tumorigenesis.
  • The expression of genes and proteins involved in the biosynthesis (histidine decarboxylase, HDC), action (histamine receptors: HRH1-HRH4), and metabolism of histamine is largely unknown both in the normal human adrenal cortex and in adrenocortical tumors.
  • In this study, we examined the expression of histamine-related genes and proteins and histamine content in normal adrenal cortex, benign adrenocortical adenomas, and malignant adrenocortical cancer (ACC).
  • Fifteen normal adrenals and 43 tumors were studied. mRNA expression was examined by real time RT-PCR.
  • We found that all proteins involved in histamine biosynthesis and action are present both in the normal adrenal cortex and in the tumors studied.
  • HDC expression and histamine content was highest in the normal tissues and lower in benign tumors, whereas it was significantly less in ACCs.
  • Adrenocortical tumorigenesis might, thus, be characterized by reduced histamine biosynthesis; furthermore, different adrenocortical tumor subtypes may show unique histamine receptor expression profiles.
  • [MeSH-major] Adrenal Cortex / metabolism. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Histamine / metabolism. Histidine Decarboxylase / metabolism. Receptors, Histamine / metabolism

  • Hazardous Substances Data Bank.